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ABSTRACT 
 
Kayla M. Peck: Characterizing the Biochemical Determinants Governing  
MERS-Coronavirus Host Range  
(Under the direction of Christina Burch and Mark Heise) 
Coronaviruses are a diverse family of viruses that infect a wide range of hosts, including 
both mammalian and avian species. Within recent history, coronaviruses have expanded their 
host range into humans, with four emergence events resulting in infections that cause only mild 
disease. However, two additional emergence events resulted in outbreaks of severe disease, 
causing heightened concern for public health. The 2003 severe acute respiratory syndrome 
coronavirus (SARS-CoV) emerged in Southeast Asia and rapidly spread around the world with a 
9 percent mortality rate before being controlled by public health intervention strategies. In 2012, 
Middle East respiratory syndrome coronavirus (MERS-CoV) emerged from its zoonotic 
reservoir. To date, it has infected over 1800 people with a 36 percent mortality rate and is still 
circulating in the population. Due to the emergence of coronaviruses with pandemic potential, it 
is important to understand how these lineages have been able to expand their host range to infect 
new species. One key determinant of viral host range is the interaction between the virus spike 
protein and the host cell receptor. For MERS-CoV specifically, the virus can infect bats, camels 
(the putative intermediate host species), and humans, but is unable to infect mice or other 
traditional small animal models due to receptor incompatibilities. The inability of MERS-CoV to 
infect any small animal model species leaves us unable to study pathogenesis or begin to develop 
potential vaccines or therapeutics. Here, I present work on the biochemical determinants that 
govern MERS-CoV host range. Specifically, I 1) characterize the interactions between the 
iv 
MERS-CoV receptor binding domain and the mouse cell receptor; 2) investigate biochemical 
determinants that govern infection for other species; 3) attempt to generate a mouse-adapted 
MERS-CoV; and 4) present an approach to investigate potential evolutionary mechanisms of 
coronavirus host range expansion. This work has contributed to the development of a small 
animal model, allowing us to begin pathogenesis studies. Additionally, understanding the 
biochemical determinants and evolutionary mechanisms of coronavirus host range expansion can 
help evaluate the pandemic potential of currently circulating zoonotic strains and better prepare 
us for future pathogenic coronaviruses that may emerge. 
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INTRODUCTION 
0.1 Virus Evolution 
Viruses are small infectious agents that replicate by infecting the cells of other organisms. 
Their general structure includes genomic material, RNA or DNA, a protein coat (capsid) that 
protects the genome, and sometimes an envelope that surrounds the capsid. Despite the small 
number of components, viruses accomplish a surprising amount of diversity, with breadth in 
what organisms they infect, their life-cycle strategies, and the impact they have on their hosts. In 
fact, estimates suggest that there are over 320,000 different viral species that infect mammals 
(Anthony et al. 2013a). If this number is extrapolated out to include all vertebrate species, the 
estimated number of viral species rises to over 3.6 million, representing an extraordinary amount 
of diversity. In addition to this remarkable diversity, viruses are also the most prevalent 
biological entity on the planet, with an estimated 1030 viruses in the ocean alone (Suttle 2007). 
This impressive diversity comes from the unique characteristics that define viruses. Of 
particular note is the fact that they evolve rapidly. This rapid evolution is a result of their large 
population sizes, short generation times, and elevated mutation rates, particularly for RNA 
viruses. Compared to larger organisms, viruses evolve on a time frame that we can witness and 
document in order to understand what evolutionary processes shape microbial populations. 
Importantly, this rapid evolution has severe consequences for infectious diseases. For example, 
influenza A virus changes dramatically each year, requiring a new vaccine to be produced and 
distributed each outbreak season. Additionally, viruses can rapidly evolve to infect new species, 
or expand their host range; when viruses expand their host range to infect humans, it can have 
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severe consequences for public health. However, despite these negative aspects of rapid viral 
evolution, it also allows us to use viruses as model systems for investigating and understanding 
evolutionary processes.  
One of the fundamental facets of evolution is the rate at which populations evolve. 
Unfortunately, the dynamics that govern the rate of molecular evolution for viruses are not quite 
straightforward. For other organisms, the rate of molecular evolution roughly follows neutral 
theory, which proposes that mutation rate, specifically the rate of neutral mutations, is the sole 
predictor of evolution rate (Kimura 1984). The success of this theory in estimating rates of 
evolution (Li et al. 1987, Kimura 1991, Bromham and Penny 2003) does not universally hold 
true for viruses, with molecular clock dynamics both supported (Gojobori et al. 1990, Leitner 
and Albert 1999) and refuted (Jenkins et al. 2002). The diversity and complexity of viral life 
cycles complicates our ability to understand the precise relationship between viral evolution rate 
and neutral theory. 
As an important component of determining the evolution rate, viral mutation rates are 
noteworthy in that they span a broad range of values. DNA viruses can have rates as low as 10-8 
substitutions per nucleotide site per cell infection (s/n/c) while RNA viruses can have rates as 
high as 10-3 (s/n/c) (Drake 1993, Sanjuan et al. 2010) (Figure 0.1). Previous studies have found 
that the relationship between evolution rate and mutation rate is linear for slowly mutating 
viruses (DNA and double-stranded RNA viruses) (Sanjuan 2012). However, this linear 
relationship breaks down for faster mutating viruses (single-strand RNA and retroviruses) 
(Sanjuan 2012) (Figure 0.1). This suggests that although faster mutating viruses have higher 
evolution rates, they cannot achieve indefinitely increasing evolution rates with increasing 
mutation rates; at some point, the mutation rate is so high that the virus population approaches 
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the error or extinction threshold (Eigen 1993, Bull et al. 2005). At this threshold, the population 
is overwhelmed with abundant transient deleterious mutations which arise more rapidly than can 
be removed by natural selection (Holmes 2003, Bull et al. 2007), causing the population to die 
out. Including the proportion of deleterious mutations into a model of evolution rate greatly 
improves the ability to explain empirical evolution rates seen for rapidly mutating viruses 
(Sanjuan 2012). Additionally, because of the diversity of virus life cycles, including within-host 
parameters, specifically the within-host reproductive ratio, also improves explanatory power 
(Peck et al. 2015a). With the increasing amount of available data on empirically estimated 
parameter values, we can improve our ability to understand what components influence the 
current evolution rates of viruses. 
 
Figure 0.1: Virus evolution rate against mutation rate 
Log-scale mean evolution rates (K) against mutation rates (µ) for each Baltimore class (data 
from Sanjuan (2012) and Sanjuan et al. (2010), respectively). (+)ssRNA, positive-sense single-
stranded RNA; (-)ssRNA, negative-sense single-stranded RNA; dsRNA, double-stranded RNA; 
Retro, retroviruses; ssDNA, single-stranded DNA; dsDNA, double-stranded DNA.  
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One important component of virus evolution is host range expansion, or the ability to 
infect a new species. The infection of a new species, whether by adaptation or by exposure from 
geographic proximity, represents a new niche that a virus can explore, promoting adaptive 
radiation (Nichol et al. 1993, Rainey and Travisano 1998, MacLean and Bell 2002, Chow et al. 
2004). Many viruses that infect the human population originated from a zoonotic source (Daszak 
et al. 2000, Taylor et al. 2001). The prevalence of zoonotic viruses that have gained the ability to 
infect humans is largely due to their rapid evolution rate; approximately one new emerging virus 
disease occurs each year (Howard and Fletcher 2012). RNA viruses, in particular, represent the 
majority of viral species that have emerged into humans (Howard and Fletcher 2012). This is 
often attributed to their high mutation rates, which result in a faster evolution rate (Figure 0.1). 
These higher rates of evolution enhance the ability with which viruses can expand into 
previously uninfected species. Unfortunately, the specific selective pressures that precede a host 
range expansion event are unknown; additionally, many of the evolutionary mechanisms that 
facilitate host range expansion for viruses still remain to be elucidated. Here, I examine virus 
evolution specifically in the context of viral host range expansion in order to better understand 
the dynamics that link mutation rate, evolution rate, emergence, and public health. 
0.2 Host Range Expansion 
Host range expansion is a complex process with many components determining which 
viruses can expand their host range and which species those hosts may comprise. Simply, there 
are three main steps for a pathogen to successfully expand its host range. The first step is 
exposure. In many cases, host jumps are caused by ecological factors that either change the 
proximity of species to each other or change the density of either species, increasing the 
likelihood of exposure (Holmes and Rambaut 2004).  
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The second step is for the pathogen and host to be compatible on a number of levels (e.g. 
by route of transmission, cell receptor, and/or infectious dose). Arguably, the most crucial barrier 
in this step for viruses is utilization of a new host species cell receptor by the viral spike protein, 
which is responsible for attachment and entry into the host cell. However, even compatibility 
between these two components may not be enough; for example, some viruses require specific 
host cell factors like proteases to facilitate viral entry (Gierer et al. 2013, Shirato et al. 2013, 
Millet and Whittaker 2015). Physiology can also play an important role; differences in the 
temperatures of human and avian airways are a crucial barrier in preventing avian influenza A 
viruses from replicating efficiently in humans (Scull et al. 2009).  
The third step is for the pathogen to be efficiently transmitted between individuals of the 
new host species (Woolhouse et al. 2005). Most zoonotic pathogens are not effectively 
transmitted between humans (Woolhouse and Gowtage-Sequeria 2005), causing humans to act as 
a dead end host in these scenarios. However, if a zoonotic virus is compatible with human cells 
and is able to transmit efficiently between humans, it has the potential to result in a severe 
outbreak. For example, although the avian influenza A virus H5N1 has been transmitted multiple 
times to humans from avian species, its inability to transmit reliably between humans is a 
primary hypothesis for the absence of a H5N1 pandemic (Hayden and Croisier 2005).  
Successful emergence of a virus into a new host species occurs when all of the above 
requirements have been met. After emergence, viruses can either become specialists by adapting 
specifically to the environment of the new host; or, they can become generalists by maintaining 
the ability to infect the ancestral species. Examples of each of these include the specialist HIV, 
which originated from a primate (Gao et al. 1999), but has changed such that HIV can no longer 
infect non-human primate species. Rabies virus, however, is a generalist in that it is capable of 
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efficiently infecting a wide range of mammalian species (Rupprecht et al. 2002). Note that while 
rabies virus is not commonly transmitted between humans, this is likely due to behavioral 
dynamics and not due to the biological inability of the virus to be transmitted. Previous studies 
have investigated what potential drivers can lead to the selection of a specialist or generalist 
virus population (Bono et al. 2012) with advantages and disadvantages of both infection 
strategies.  
0.3 Coronaviruses 
Here I focus on coronaviruses, a diverse family of viruses that has expanded its host 
range many times over the course of its evolutionary history. Coronaviruses are enveloped, 
single-stranded positive-sense RNA viruses with particularly large genomes (28-32 kb) that can 
infect a wide range of avian and mammalian hosts. Genomes contain a 5’ cap and 3’ poly-A tail, 
with the genome organization divided into nonstructural protein genes and structural and 
accessory genes. The core structural proteins include S (spike), E (envelope), M (matrix), and N 
(nucleocapsid) proteins. While accessory genes vary among coronaviruses, and may include 
some strain-specific structural glycoproteins, the order of the structural proteins is highly 
conserved as S, E, M, and N. The ~180 kDa spike glycoprotein (S) mediates entry into the host 
cell and surrounds the virus particle, yielding a crown-like appearance. Coronaviruses utilize a 
variety of cellular proteins as receptors (Perlman and Netland 2009, Graham et al. 2013), with 
cleavage of the spike protein crucial for mediating virus-host membrane fusion and subsequent 
entry into the cell.  
Bats, rodents, and birds act as the natural reservoir species for many coronaviruses (Li et 
al. 2005a, Woo et al. 2009, Wang et al. 2015), but host range expansion has been prevalent, with 
over 20 species currently able to be infected by coronaviruses (Figure 0.2). To date, six human 
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coronaviruses (HCoV) have been identified, with each of these hypothesized to have originated 
as a zoonotic strain that underwent host range expansion. Of these six HCoVs, four are 
associated with mild respiratory disease: HCoV-229E, HCoV-HKU1, HCoV-NL63, and HCoV-
OC43. Two of these (HCoV-229E and HCoV-NL63) are thought to have originated from bats. 
While the standing hypothesis for HCoV-OC43 was that it likely emerged from a bovine 
reservoir species (Vijgen et al. 2005), new analyses suggest that the original host of this lineage, 
and perhaps HCoV-HKU1 as well, may have been a murine species (Lau et al. 2015). In addition 
to HCoVs that cause mild symptoms, two strains have emerged to cause severe disease, 
including severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East 
respiratory syndrome coronavirus (MERS-CoV). These two viruses combined have resulted in 
over 1,100 deaths, with MERS-CoV still circulating in the human population, causing 
heightened concern due to the lack of vaccines or therapeutics. The threat to public health caused 
by the emergence of these highly pathogenic strains into humans draws attention to the 
importance of understanding both the biochemical and evolutionary mechanisms of coronavirus 
host range expansion.   
The selective pressures that drive coronavirus host range expansion are not yet 
understood. Additionally, a pattern of coronavirus host range characteristics or biases is not yet 
evident. Some coronaviruses appear to be generalists, capable of infecting many different orders 
of mammals. For example, Betacoronavirus 1 has been detected in dogs, humans, and numerous 
ungulate species (Erles et al. 2003, Hasoksuz et al. 2007, Alekseev et al. 2008). Other 
coronaviruses have been detected in only a single mammalian order, such as the many SARS-
like coronaviruses that have been detected only in bats (Tang et al. 2006, Drexler et al. 2010). 
Bats exist as the largest reservoir for coronaviruses, potentially due to their diversity,  
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Figure 0.2: Phylogenetic tree of whole-genome length coronavirus sequences 
Phylogenetic tree of a subset of coronaviruses representing groups 1, 2, and 3 (the alpha-, beta-, 
and gammacoronaviruses; colors represent each designated group/clade). The newly discovered 
deltacoronavirus clade is not depicted. Sequences were aligned using MAFFT (Katoh et al. 
2002). The phylogenetic tree was generated using maximum likelihood with the PhyML package 
(Guindon et al. 2010) and visualized using EvolView (Zhang et al. 2012). Circles denote human 
coronavirus strains; gray indicates viruses that cause mild symptoms and black indicates viruses 
that have emerged to cause severe disease. Of note is that coronaviruses within the same clade 
infect many species. See Appendix A for strain abbreviation key and NCBI accession numbers. 
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immunology, physiology, and ability to traverse wide geographic regions during seasonal 
migrations (Dobson 2005, Calisher et al. 2006). Due to this, metagenomics analyses have 
focused on examining the diversity and prevalence of coronaviruses in bats. Studies have found 
varying levels of coronavirus diversity in bat populations in North America (Donaldson et al. 
2010) and China (Ge et al. 2012, Wu et al. 2012b), as well as detecting individual strains in bat 
populations worldwide (reviewed in Drexler et al. 2014). Furthermore, novel coronaviruses 
continue to be discovered globally, with recent findings coming from Mexico (Anthony et al. 
2013b), Brazil (Goes et al. 2013), and South Africa (Ithete et al. 2013). Continued efforts to 
sample bat populations worldwide will help us better estimate the diversity and prevalence of 
coronaviruses, as well as more thoroughly map their phylogenetic relationships. 
The biggest threat to the public health comes from coronaviruses that emerge into the 
human population to cause severe disease. The first of these, SARS-CoV, emerged from bats 
into the human population in 2003 and infected over 8,000 people with a 9.6% mortality rate 
before it was controlled by public health measures (Cherry 2004). Despite the awareness raised 
for coronaviruses during this outbreak, reconstructing the evolutionary path that led to the host 
range expansion of SARS-CoV has been surprisingly difficult. SARS-CoV is closely related to 
bat coronaviruses, with up to 92% nucleotide sequence identity to its closest detected relative (Li 
et al. 2005a). However, no virus identical to SARS-CoV has ever been isolated from bats, raising 
suspicion on whether the virus did actually emerge from this reservoir species. Data in support of 
an origin from bats include an analysis of the SARS-CoV receptor, angiotensin-converting 
enzyme 2 (ACE2). The bat ACE2 gene was found to show the signature of recurrent positive 
selection (dN/dS > 1) (Figure 0.3A), suggesting that a SARS-like coronavirus was circulating in 
the bat population before emerging into humans (Demogines et al. 2012). Data refuting the bat 
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origin hypothesis include the fact that, initially, no bat coronaviruses were found to utilize ACE2 
or any ACE2 ortholog (Ren et al. 2008). In fact, it took over a decade before researchers were 
able to identify a SARS-like coronavirus capable of utilizing human, civet, and Chinese 
horseshoe bat ACE2 for cell entry (Ge et al. 2012). The discovery of this virus (bat SL-CoV- 
WIV1) provides strong evidence that SARS-CoV originated from a bat reservoir (see Figure 
0.2). Currently, the best supported hypothesis is that an intermediate host species, specifically the 
civet, played an important role in facilitating the host range expansion event, either by imposing 
a specific selective pressure or by putting the virus into close proximity with humans (reviewed 
in Wang and Eaton 2007, Plowright et al. 2015). However, the identification of bat SL-CoV-
WIV1 suggests that an intermediate host may not have been required for emergence of SARS-
CoV into humans. Further research is needed to determine the precise mutational and cross-
species path of SARS-CoV in order to help reveal how new human pathogens emerge. 
 
Figure 0.3: Positive selection on coronavirus host cell receptors 
(A) Human ACE2 (light blue) bound to the SARS-CoV receptor-binding domain (red) (PDB 
2AJF), with homologous residues under positive selection in bats labeled (Demogines et al. 
2012). (B) Human DPP4 (green) bound to the MERS-CoV RBD (purple) (PDB 4L72), with 
homologous residues under positive selection in bats labeled (Cui et al. 2013). Structures 
visualized using PyMOL. From Peck et al. 2015c. 
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In 2012, MERS-CoV emerged into the human population in Saudi Arabia. As of 
November 2016, there were 1,813 confirmed cases with a 36% mortality rate (WHO 2016). 
MERS-CoV is grouped phylogenetically into the C betacoronavirus clade along with the bat 
coronaviruses BtCoV-HKU4 and BtCoV-HKU5 (Figure 0.2) (van Boheemen et al. 2012, 
Drexler et al. 2014, Peck et al. 2015c). Unlike SARS-CoV, MERS-CoV utilizes dipeptidyl 
peptidase 4 (DPP4) as an entry receptor (Raj et al. 2013). To date, only MERS-CoV and BtCoV-
HKU4 have been found to utilize DPP4 (Wang et al. 2014, Yang et al. 2014); the presence of a 
closely related bat coronavirus that uses the same host cell receptor as MERS-CoV provides 
strong support for the emergence of MERS-CoV from a bat lineage. Adaptation of MERS-CoV 
to humans specifically is supported by the fact that MERS-CoV utilizes human DPP4 (hDPP4) 
more efficiently than bat DPP4 (bDPP4), yet BtCoV-HKU4 utilizes both with equivalent 
efficiency (Yang et al. 2014). Thus far, the host cell receptors of BtCoV-HKU5 and other closely 
related group 2c coronaviruses have not been identified. 
The similarity between MERS-CoV and group 2c bat coronaviruses (Figure 0.2) strongly 
suggests that MERS-CoV originated from bats. Additionally, similar to the SARS-CoV story, 
bDPP4 has been found to be under strong positive selection (Figure 0.3), which may be due to 
the circulation of DPP4-utilizing coronaviruses in bats (Cui et al. 2013). It is not clear whether 
this signal is from the progenitor of MERS-CoV or from other coronaviruses that utilize DPP4, 
such as BtCoV-HKU4. As with SARS-CoV, the ancestral virus has been elusive, with no 
detection of a full-length MERS-CoV sequence in a bat population to date. The best example has 
been a coronavirus isolate from a bat population where a 190-nucleotide fragment of the RNA 
dependent RNA polymerase (RdRp) gene was 100% identical to MERS-CoV (Memish et al. 
2013). Since this discovery, bat coronaviruses with high sequence similarity to MERS-CoV have 
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been detected in geographic regions very distant from its original emergence location in Saudi 
Arabia. RdRp gene sequences with 96.5% and 99.6% amino acid identity to MERS-CoV were 
detected from bat populations in Mexico (Anthony et al. 2013b) and South Africa (Ithete et al. 
2013), respectively. These discoveries emphasize the importance of further metagenomics 
analyses of bat viromes in widespread geographic locations. 
Looking at the phylogenetic tree of coronaviruses (Figure 0.2), the lineages that have 
emerged into humans occupy several clades. This suggests that there is not a single lineage of 
zoonotic coronaviruses that is capable of expanding its host range into humans. Instead, many 
lineages have been able to emerge into the human population. Additionally, these lineages utilize 
different host cell receptors for entry into the cell. SARS-CoV and HCoV-NL63 utilize ACE2 
(Li et al. 2003, Hofmann et al. 2005), MERS-CoV utilizes DPP4 (Raj et al. 2013), and HCoV-
229E utilizes a protein known as aminopeptidase N (APN) (Yeager et al. 1992). The receptor 
molecules of HCoV-HKU1 and HCoV-OC43 have not yet been identified, however the presence 
of O-acetylated sialic acid has been shown to serve as a receptor determinant (Krempl et al.1995, 
Huang et al. 2015). The diversity of receptors utilized, combined with the large number of 
species that coronaviruses have evolved to infect, poses the question of whether coronaviruses 
have an increased capacity for host range expansion relative to other RNA viruses. Perhaps there 
are unique characteristics of coronaviruses that increase their ability to emerge into new species, 
providing an interesting case study of the evolution of host range. 
0.4 Overview of Chapters 
This dissertation focuses on understanding the recent host range expansion of MERS-
CoV from a biochemical and evolutionary perspective. Chapter 1 investigates the biochemical 
determinants of permissivity to MERS-CoV in the context of the mouse host cell receptor. The 
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interactions between the MERS-CoV receptor binding domain (RBD) and the human and mouse 
DPP4 orthologs are analyzed both computationally and experimentally to provide data on what 
particular residues and residue properties are important for mediating MERS-CoV permissivity. I 
find that two residues are capable of mediating this interaction; two amino acid changes within 
the mouse DPP4 (mDPP4) backbone allow it to successfully support infection. The biochemical 
explanation behind these two changes is 1) the strengthening of a hydrophobic core in the 
MERS-CoV RBD and 2) the removal of a non-conserved glycosylation site. Data gathered from 
this chapter helped generate a transgenic mouse model that will be utilized to study MERS-CoV 
pathogenesis. 
Chapter 2 investigates whether there is a broader signature of permissivity in additional 
DPP4 orthologs. Other traditional small animal model species, namely ferrets, guinea pigs, and 
hamsters, are also nonpermissive to MERS-CoV infection. Using the insight gained in my 
previous experiments, I determine whether the same biochemical mechanisms that conferred 
permissivity of mDPP4 to MERS-CoV are applicable to these other species. Many 
nonpermissive species have glycosylation sites near the location that aligns with the mDPP4 
motif, suggesting that this may potentially be a broadly acting mechanism for blocking MERS-
CoV infection. I find that although successful infection is never achieved without removal of 
glycosylation in these orthologs, the interaction dynamics are more complex, suggesting that 
there are other important key determinants that will require more work to reveal. 
Chapter 3 turns to the field of evolutionary biology in order to determine how 
coronaviruses may expand their host range when receptor incompatibilities are the primary 
barrier. Using the toolkit established in Chapters 1 and 2, I attempt to adapt MERS-CoV to 
utilize the wildtype mDPP4 molecule. However, due to the likely requirement of multiple 
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mutations, including remodeling of the RBD to bind around the mDPP4 glycan, there was no 
adaptation of MERS-CoV to wildtype mDPP4. One potential hypothesis is that there was not 
enough genetic variation present in the population to achieve the multiple mutations required for 
successful binding (contingent on it being biologically possible). In Chapter 4, I present future 
directions for generating a MERS-CoV mutator that can be utilized in adaptation experiments to 
enhance the sequence space accessible by the viral population. Mutations in the nsp14 gene of 
coronaviruses have been found to generate elevated mutation rates, allowing mutators to be a 
possible characteristic that permits coronaviruses to expand their host range more frequently, and 
with more success, than other viruses. 
The increasing prevalence of emerging pathogens heightens the need to understand the 
biochemical and evolutionary dynamics of host range expansion events. Coronaviruses, 
particularly, draw attention due to the recent emergence of highly pathogenic strains that lack 
effective vaccines or therapeutics. For many viruses, including SARS-CoV and MERS-CoV, the 
specific factors contributing to the host range expansion into humans are still unclear. 
Elucidating the selective pressures imposed on the virus populations will help reveal the specific 
path of emergence of SARS-CoV and MERS-CoV. Understanding the adaptation pathway of 
coronaviruses to new species will help us better catalogue the selective pressures driving host 
range expansion and will provide a framework for which we can set up ecological and/or 
geographical preventative measures. Although the limited number of outbreak events in 
coronaviruses reduces our ability to create a comprehensive picture of key host range expansion 
determinants, understanding the potential contribution of different biochemical and evolutionary 
mechanisms is a useful place to start.  
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CHAPTER 1: BIOCHEMICAL DETERMINANTS OF MOUSE DPP4 PERMISSIVITY TO 
MERS-CORONAVIRUS 
1.1 Introduction 
Coronaviruses have expanded their host range into humans multiple times over the course 
of their evolutionary history (reviewed in Peck et al. 2015c). In recent history, two of these 
events have resulted in viruses with pandemic potential. MERS-CoV jumped into humans in 
2012, providing the second case of a coronavirus emergence event resulting in severe disease. As 
of November 2016, MERS-CoV has infected over 1,800 people, with a 36% percent mortality 
rate (WHO 2016). Despite being similar to SARS-CoV in that it causes severe disease, MERS-
CoV shares only 57% sequence identity with SARS-CoV and utilizes a different host cell 
receptor. Whereas SARS-CoV utilizes ACE2 for entry (Li et al. 2003), MERS-CoV utilizes 
DPP4 (Raj et al. 2013). DPP4 is a cell-surface protease that has a catalytic role in selectively 
removing the N terminus from certain peptides (Lambeir et al. 2003). It has been well studied 
due to the role it plays in glucose metabolism, immune responses, adhesion, and apoptosis 
(Boonacker and Noorden 2003). MERS-CoV was the first coronavirus identified to utilize this 
receptor, although since then the bat coronavirus BtCoV-HKU4 has also been found to utilize 
DPP4 (Yang et al. 2014). To date, MERS-CoV is known to successfully enter cells utilizng 
DPP4 from humans, nonhuman primates, bats (de Wit et al. 2013b), rabbits (Haagmans et al. 
2015), camels, horses, and to a lesser extent goats (Barlan et al. 2014, Eckerle et al. 2014). 
However, it is unable to enter cells using DPP4 from traditional small animal model species such 
as mice (Cockrell et al. 2014, Coleman et al. 2014), ferrets (Raj et al. 2014), and hamsters (de 
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Wit et al. 2013a, van Doremalen et al. 2014). This species restriction prevents the adequate study 
of MERS-CoV pathogenesis and limits the development of vaccine strategies or alternate 
therapeutics. Understanding the determinants that mediate MERS-CoV permissivity in these 
species will provide novel insights into interactions between the MERS-CoV RBD and DPP4, as 
well as help in the development of new small animal models. 
1.2 Identify key mutations in mouse DPP4 that allow it to support MERS-CoV infection 
(modified from Cockrell et al. 2014) 
In order to investigate the relationship between MERS-CoV and DPP4, we designed an 
ectopic expression system utilizing the 945ΔRRE expression vector, a lentiviral vector derived 
from pTK945, to constitutively express the human and mouse DPP4 genes in human embryonic 
kidney 293T (HEK 293T) cells. These cells lack detectable endogenous expression of hDPP4 
(Zhao et al. 2013). Both orthologs were expressed either as full-length proteins or as fusions to 
the Venus protein at the carboxy terminus as a marker of green fluorescence. HEK 293T cells 
were transfected with 3 µg of the appropriate DPP4 expression plasmid. At ~24 hours post-
transfection, cells were infected at a multiplicity of infection (MOI) of 5 with a recombinant 
MERS-CoV strain designed to express tomato red fluorescent protein (rMERS-CoV-RFP) 
(Figures 1.1A and B). This rMERS-CoV strain is derived from the original EMC2012 isolate 
(van Boheemen et al. 2012) and was previously demonstrated to infect and replicate in a manner 
similar to wildtype MERS-CoV (Scobey et al. 2013). Cells were imaged ~24 hours post-
infection (hpi) by rMERS-CoV-RFP. High transfection efficiency was seen by visualizing the 
DPP4-Venus fusion constructs (Figures 1.1A and B). 
Cells expressing hDPP4 were readily infected with rMERS-CoV-RFP virus (Figure 
1.1A), whereas overexpressing mDPP4 did not result in infection (Figure 1.1B). In fact, 
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overexpression of mDPP4 showed levels of infection that were equivalent to control HEK 293T 
cells (Figure 1.1B). To confirm that mDPP4 was being expressed, and a negative infection  
 
Figure 1.1: MERS-CoV infection utilizing hDPP4 and mDPP4 
mDPP4 does not support MERS-CoV infection. HEK 293T cells were transfected with 3 µg of 
plasmid expressing (A) hDPP4 or hDPP4-Venus fusion and (B) mDPP4 or mDPP4-venus fusion. 
At ~24 hours post-transfection, cells were infected with rMERS-CoV-RFP virus at an MOI of 5. 
Venus fusion proteins were assessed by fluorescence microscopy at ~48 hours post-transfection. 
In independent experiments, infection with rMERS-CoV-RFP virus was assessed for red cells by 
fluorescence microscopy at ~18 hpi. (C) Western blot analysis demonstrates overexpression of 
mDPP4 and hDPP4. Extracts were prepared at ~48 hours post-transfection using AV lysis buffer 
(Agnihothram et al. 2014), and samples were heat inactivated for 60 min at 90 °C for removal 
from a BSL3 facility and resolved on an 8% SDS-PAGE gel. Blots were probed with primary 
goat-anti-DPP4 polyclonal antibody (R&D Systems) at 1:1,000 in 1X Tris TBST or goat anti-
actin polyclonal antibody (Santa Cruz) and detected with a secondary rabbit anti-goat–HRP-
conjugated antibody (Sigma) at 1:10,000 in 1X TBST in 5% milk. (D) Western blot analysis of 
MERS-CoV S and N proteins. Lysates were collected at ~18 hpi and treated as in panel C. Blots 
were probed with primary mouse polyclonal antiserum at 1:400, raised to S and N proteins as 
described previously (Agnihothram et al. 2014), and detected with a secondary goat anti-mouse–
HRP (GE Healthcare) at 1:10,000 in 1X TBST in 5% milk. From Cockrell et al. 2014. 
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readout was not based on absence of the protein, we performed Western Blot analyses to detect 
the presence of mDPP4 after transfection into HEK 293T cells (Figure 1.1C). Bands present at 
~110 kDa for both hDPP4 and mDPP4 indicate successful expression of both constructs. 
Additionally, Western blot analysis for MERS-CoV spike (S) and nucleocapsid (N) proteins 
show detection of both viral proteins in cells expressing hDPP4 but not mDPP4 (Figure 1.1D). 
These results support hDPP4, but not mDPP4, as a functional receptor for MERS-CoV (Cockrell 
et al. 2014). 
The crystal structure of hDPP4 complexed with the MERS-CoV RBD (Lu et al. 2013, 
Wang et al. 2013) shows that blades IV and V of the β-propeller domain primarily interact with 
the MERS-CoV RBD (Figure 1.2C). Unfortunately, the crystal structure of mDPP4 has not yet 
been solved. This limits our ability to analyze the binding interactions between mDPP4 and the 
MERS-CoV RBD computationally. Due to this limitation, we first set out to test whether the 
mDPP4 backbone was capable of acting as an entry receptor for MERS-CoV. We generated a 
chimeric DPP4 molecule that introduced residues 273 through 340 (chDPP4 (273-340)) from 
hDPP4 into mDPP4 using overlap extension PCR (Figure 1.2A) (Cockrell et al. 2014). These 
residues compose the regions of blades IV and V that interact with the MERS-CoV RBD. Within 
this region, there are 22 different amino acid identities between hDPP4 and mDPP4 (Figure 
1.2A), suggesting that there may be important differences within this region that prevent mDPP4 
from acting as a functional receptor. Expressing chDPP4 (273-340) in HEK 293T cells shows 
that these cells are equivalently susceptible to cells expressing hDPP4 (Figure 1.2B). These 
results indicate 1) that the hDPP4 residues 273 to 340 confer MERS-CoV permissivity to 
mDPP4 and 2) that the mDPP4 molecule as a backbone is capable of supporting MERS-CoV 
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infection. Thus, there must be important differences between blades IV and V of hDPP4 and 
mDPP4 that determine permissivity. 
 
Figure 1.2: mDPP4 as a backbone can support MERS-CoV infection 
Blades IV and V from the β-propeller of hDPP4 make mDPP4 permissible to MERS-CoV 
infection. (A) Vector NTI protein sequence alignment of human (top strand) and mouse (bottom 
strand) DPP4 molecules. Yellow highlighted regions indicate conserved amino acids, white 
regions signify amino acids that are functionally different (i.e., hydrophobic and hydrophilic), 
and green highlighting indicates amino acids that are different but functionally similar (i.e., the 
threonine and serine are both polar and uncharged). (B) HEK 293T cells were transfected with 
the indicated DPP4. At ~20 hours post-transfection, cells were infected with rMERS-CoV-RFP 
virus at an MOI of 5, and infection was assessed ~18 hpi by fluorescence microscopy. (C) 3D 
molecular PyMOL software was employed to visualize the mDPP4 structure overlaid onto the 
hDPP4 structure. The hDPP4 structure was based upon the crystal structure resolved in context 
with the MERS S RBD (PDB code 4L72). MERS S protein is displayed in red, hDPP4 in yellow, 
and mDPP4 in blue. The mDPP4 sequence was threaded using the I-TASSER software (Zhang 
2008). The expanded view depicts the DPP4 region at the interaction surface. Numbered and 
highlighted are the specific amino acids chosen for mutation in the mDPP4 protein. From 
Cockrell et al. 2014. 
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In order to further explore the differences between hDPP4 and mDPP4 in this region, we 
threaded the mDPP4 molecule using I-TASSER (Zhang 2008) to produce a predicted protein 
structure. Overlaying the resulting molecule with hDPP4 and employing three-dimensional (3D) 
visualization using PyMOL (Molecular Graphics System, Version 1.6.0.0 Schrodinger, LLC) 
shows that overall, these two proteins are highly similar in structure (Figure 1.2C), keeping in 
mind that we are using a predicted structure for mDPP4. This supports our experimental findings 
that the mDPP4 molecule can act as a backbone to support infection and that there are important 
differences at the interface of the receptor and the virus RBD. 
Due to a lack of obvious structural differences, we computationally interrogated the 
interface of mDPP4 and the MERS-CoV RBD to determine what amino acid differences 
between hDPP4 and mDPP4 might explain the differences in permissivity. Based on analysis in 
Rosetta (Rohl et al. 2004), we identified five functionally variant surface amino acids in this 
region of mDPP4 that may affect MERS-CoV binding. Using overlap extension PCR, we 
generated various chimeric mDPP4 molecules corresponding to the changes introduced based on 
the hDPP4 amino acid identities. These mutations include P282T, A288L, R289I, T330R, and 
V340I (residue numbering relative to mDPP4) (Figure 1.3A). HEK 293T cells were transfected 
with the indicated chimeric mDPP4 construct. At ~20 hours post-transfection, cells were infected 
with rMERS-CoV-RFP at an MOI of 1 and imaged ~18 hpi. A chimeric mDPP4 molecule with 
all five identified mutations (chDPP4 (5 mut)) showed MERS-CoV infection comparable to that 
of hDPP4 (Figure 1.3B). This suggests that one or more of these mutations may be sufficient for 
mediating MERS-CoV permissivity in the context of mDPP4. Previous structural studies of 
hDPP4 suggest that two distinct interactions are important for MERS-CoV binding, specifically 
one interaction on blade IV and one on blade V (Wang et al. 2013). Our set of identified 
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mutations includes two located on blade IV (T330R and V340I) and three on blade V (P282T, 
A288L, and R289I). These two sets of mutations were introduced independently into mDPP4 in  
 
Figure 1.3: MERS-CoV infection is dependent upon specific amino acids in DPP4 
(A) Vector NTI protein sequence alignment of hDPP4 (top strand) with chDPP4 (middle strand) 
and mDPP4 (bottom strand) indicating positions of introduced human mutations with red arrows. 
(B) HEK 293T cells were transfected with the indicated DPP4 molecule. At ~20 hours post-
transfection, cells were infected with rMERS-CoV-red virus at MOI of 1, and infection was 
assessed ~18 hpi by fluorescence microscopy. (C) In an independent experiment, cells 
overexpressing the indicated DPP4 constructs were infected with rMERS-CoV-red virus at MOI 
of 0.1, 0.01, and 0.001 on six-well plates. At ~18 hpi, cells were scored at the following MOI: no 
DPP4 and mDPP4, 0.1; chDPP4 P282T A288L R289I T330R V340I [“chDPP4 (5 mutations)”] 
and chDPP4 A288L T330R, 0.01; and hDPP4, 0.001. Values were normalized to an MOI of 0.1 
and expressed as relative infection at 0.1. Human DPP4, chDPP4 P282T A288L R289I T330R 
V340I, and chDPP4 A288L T330R showed a significant increase in infection over mDPP4 (*, P 
< 0.05, Student’s t test). (D) Western blots demonstrating overexpression of hDPP4, mDPP4, 
and each chDPP4 molecule, N protein of infected cells, and β-actin as a loading control. Western 
blots were prepared and probed as described in Figure 1.1C and D. From Cockrell et al. 2014. 
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order to test their impact on permissivity to rMERS-CoV-RFP. Neither set recapitulated the 
levels of infection seen when all five mutations were included (Figure 1.3B). Further 
investigation led us to introduce each mutation singly and determine the impact on receptor 
permissivity. This experiment revealed that A288L and T330R were partly responsible for the 
observed increase in infection from each group (on blades V and IV, respectively) (Figure 1.3B). 
This conclusion is supported by Western blot analysis, which shows the detection of N protein in 
infected cells expressing the A288L or T330R construct, but not the other three individual 
mutants (Figure 1.3D). Combining these two mutations into a single construct (chDPP4 288, 
330) results in high levels of infection by rMERS-CoV-RFP that are comparable to when all five 
mutations are included (Figure 1.3B). Quantifying the number of MERS-CoV-infected red cells 
reveals that chDPP4 288, 330 exhibits nearly a 1.5-log increase in infection compared to mDPP4 
(Figure 1.3C). Western blot analysis also supports this conclusion (Figure 1.3D). Although no 
mDPP4 mutants achieved a level of infection quantitatively similar to hDPP4, the dramatic 
increase in infection offers strong support for the identified residues playing an important role in 
mediating permissivity. 
Here, we focused on receptor compatibilities between mDPP4 and the MERS-CoV RBD; 
however, other factors in the replication cycle of MERS-CoV may be incompatible in the context 
of the mouse. For example, host proteases are required to cleave the MERS-CoV spike protein in 
order to allow entry into the cell (Gierer et al. 2013, Shirato et al. 2013), and these may differ 
between species. To determine whether additional restriction factors in rodent cells may affect 
permissivity to MERS-CoV, we transfected hDPP4 and our chimeric mDPP4 constructs into 
both mouse and hamster cell lines (NIH 3T3 and BHK, respectively). Receptors that were 
permissive when transfected into HEK 293T cells were also permissive in mouse and hamster 
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cells (Figure 1.4A and B, respectively), suggesting that additional rodent-specific factors are not 
responsible for preventing MERS-CoV infection, at least in an in vitro context.  
Overall, our results indicate that successful infection by MERS-CoV requires a 
combination of at least two mutations in mDPP4 (A288L and T330R) (Cockrell et al. 2014), 
lying within blades V and IV, respectively. These results are in agreement with previous crystal  
 
Figure 1.4: Human and chimeric DPP4 molecules can support MERS-CoV infection in hamster 
and mouse cells 
(A) BHK cells were electroporated with the indicated DPP4 molecules. At ~20 hours post-
transfection, cells were seeded in 6-well plates and infected with rMERS-CoV-RFP at an MOI of 
2. (B) Mouse NIH 3T3 cells were transfected using Nucleofection (according to the Amaxa 
procedure) with the indicated DPP4 molecules. Cells were seeded into 12-well plates and 
infected with rMERS-CoV-RFP at an MOI of ~4 at 24 hours post-Nucleofection. All infections 
were assessed at ~24 hpi by fluorescence microscopy. From Cockrell et al. 2014. 
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structure data from hDPP4 and the MERS-CoV RBD, which suggest the hDPP4 equivalents 
(L294 and R336) are critical residues for binding and successful infection of MERS-CoV (Lu et 
al. 2013, Wang et al. 2013). 
Using this information, we generated a transgenic mouse using the CRISPR/Cas genome 
editing technique that engineers these two mutations into mDPP4. Whereas other mouse models 
have been developed, each comes with its own caveat that reduces the effectiveness of 
pathogenesis research. The first transgenic mouse was generated by transient adenovirus-
mediated hDPP4 expression and resulted in susceptibility to MERS-CoV (Zhao et al. 2014). 
However, the transient nature of this model, as well as immune responses that can be triggered 
by the adenovirus delivery system make this model less than ideal. The second mouse model 
produced showed global expression of hDPP4 and is also successfully infected by MERS-CoV 
(Agrawal et al. 2015). However, this model results in high viral titers in most organs including 
the brain, suggesting that additional improvements are needed to more faithfully phenocopy the 
human disease model. In addition, the enzymatic activity of DPP4 can have detrimental effects, 
particularly when the protein is overexpressed (Takasawa et al. 2010), and the impact of these 
effects in the transgenic mouse model should be explored. Our mouse model is still in the 
validation phase, and while it may come with its own set of caveats, the endogenous expression 
of mDPP4 behind its natural promoter suggests that we may overcome some of the previous 
complications. Overall, the production of an accurate mouse model will provide a new tool for 
studying pathogenesis and developing potential therapeutics. 
1.3 Identify key biochemical determinants that prevent mouse DPP4 from acting as a valid 
receptor (modified from Peck et al. 2015b) 
The functional receptor for MERS-CoV was recently identified as DPP4 (Raj et al. 
2013). Interestingly, while MERS-CoV can utilize human, bat, and camel DPP4, traditional 
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small animal models are nonpermissive, including mice (Cockrell et al. 2014, Coleman et al. 
2014), ferrets (Raj et al. 2014), and hamsters (de Wit et al. 2013a). The relevance of MERS-CoV 
as an emerging pathogen and the importance of small animal models for studying pathogenesis 
and for developing vaccines and therapeutics led us to identify the determinants of interactions 
between the MERS-CoV RBD and mDPP4. Interactions between DPP4 and the MERS-CoV 
RBD are primarily restricted to blades IV and V of the DPP4 N-terminal β-propeller domain (Lu 
et al. 2013, Wang et al. 2013). Recently, we found that two key residues in mDPP4 (A288L and 
T330R) could permit infection by MERS-CoV when mutated to the hDPP4 amino acids 
(Cockrell et al. 2014). These residues lie within blades IV and V of the β-propeller domain (see 
Lu et al. 2013, Wang et al. 2013). The importance of A288L can be understood by recognizing 
that there is a strong hydrophobic region in the MERS-CoV RBD that engages the equivalent 
hDPP4 residue (L294) (Wang et al. 2013). In fact, all permissive DPP4 orthologs have a leucine 
residue at this site (i.e. bat, camel, human, marmoset). This interaction, however, is altered in 
mDPP4, potentially making this hydrophobic region less amenable to interacting with the 
MERS-CoV RBD.  
 On blade IV, the T330R substitution in mDPP4 regulates two potentially critical virus-
host cell receptor interaction events. First, the 330 arginine provides a highly conserved charge 
that is present in all known permissive hosts, but missing from all known nonpermissive hosts 
(Figure 1.5A). In hDPP4, the interaction between this residue (R336 relative to hDPP4 
numbering) and the MERS-CoV RBD Y499 has been previously noted as a key interaction (Lu 
et al. 2013, Wang et al. 2013). The absence of this interaction could be a primary factor behind 
the lack of permissivity of mDPP4, as well as other nonpermissive DPP4 orthologs. Second, the 
T330R mutation knocks out an NXT glycosylation motif in mDPP4 (Figure 1.5A). Western Blot 
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analysis is consistent with the loss of glycosylation at this site, as evidenced by a ~2.5 kDa 
downward shift in the mDPP4 T330R mutant (Figure 1.5B). Considering these two potentially 
important effects, we hypothesized that either the introduction of the conserved charge or the 
removal of glycosylation was crucial for regulating mDPP4 permissivity to MERS-CoV 
infection. 
 
Figure 1.5: Is charge or glycosylation important for mediating mouse DPP4 permissivity? 
(A) MEGA6 (Tamura et al. 2013) protein sequence alignment of DPP4 for various permissive 
(human, camel, bat) and nonpermissive (mouse, ferret, hamster, guinea pig) species, visualized 
in GeneDoc. Residue numbers are relative to mDPP4. The mutation T330R in mDPP4 
introduces a conserved positive charge for permissive hosts, but also knocks out a glycosylation 
site. NCBI accession numbers: human, NP_001926.2; camel, AIG55259; bat, AGF80256.1; 
mouse, NP_034204.1; ferret, ABC72084.1; hamster, AIG55262.1; guinea pig, XP_003478612.2.  
(B) The downward shift in the mDPP4 T330R band is consistent with the removal of 
glycosylation. Western blot protocol follows Cockrell et al. 2014. (C) Structure of hDPP4 
(yellow) complexed with the MERS-RBD (red) (PDB code 4L72) visualized using PyMOL. 
mDPP4 (blue), threaded using I-TASSER (Zhang 2008), is overlaid to show the key mutations: 
A288L, T330R, N328A. Blue indicates wildtype mDPP4 residues while orange indicates the 
human amino acid identity. (D) DPP4 constructs used and whether they are glycosylated at the 
328 residue or whether the conserved positive arginine is present at the 330 residue (numbered 
relative to mDPP4). From Peck et al. 2015b. 
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 To test the impact of glycosylation versus charge on the ability of mDPP4 to support 
infection by MERS-CoV, we generated a panel of DPP4 mutants (Figures 1.5C and 1.5D) 
contained within the 945ΔRRE expression vector, a lentiviral vector derived from pTK945. 
DPP4 constructs were expressed in HEK 293T cells that lack detectable expression of 
endogenous hDPP4 (Zhao et al. 2013). At ~18 hours post-transfection with 3 µg of the DPP4 
expression plasmid, cells were infected with rMERS-CoV-RFP which encodes tomato red 
fluorescent protein in place of ORF5 (Scobey et al. 2013). Cells were imaged ~24 hours post-
infection to assess the number of positive cells as a readout for MERS-CoV infection. 
A set of hDPP4 mutants were generated and assayed for permissivity to MERS-CoV 
infection in order to first assess the importance of glycosylation versus charge in the human 
context. We generated two mutants: one that included a glycosylation site and one that removed 
the charge. First, we swapped the three residues of the NLT mDPP4 putative glycosylation site 
with residues 334 to 336 of hDPP4 (hDPP4 + gly). This addition shows a severe reduction in 
infection (Figures 1.6A and 1.6B), with an upward shift in the Western blot band consistent with 
successful introduction of the glycosylation site (Figure 1.6C). However, this mutation impacts 
both the glycosylation site and the charged 336 residue (aligning to residue 330 in mDPP4, 
Figure 1.5A). Therefore, our second mutant introduces the R336T mutation by itself, which 
removes the positive charge without introducing glycosylation. While we do observe a decrease 
in infection, it is not comparable in magnitude to the decrease seen when glycosylation is 
included (Figures 1.6A and 1.6B), suggesting that the presence of a positively charged residue at 
position 336 is not essential for hDPP4-mediated MERS-CoV infection. Additionally, the 
presence of glycosylation does not impact the ability of hDPP4 + gly to be expressed on the cell 
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surface (Figure 1.8). These results show that glycosylation can act to inhibit infection by MERS-
CoV and that the positive charge is not a crucial interaction in the context of hDPP4. 
In order to directly assess the relative contribution of charge versus glycosylation in the 
context of mDPP4, we evaluated whether the presence of glycosylation or charge at the 330 site 
regulates mDPP4 receptor activity. For these studies, mutations were evaluated singly and in the 
presence of the secondary mutation (A288L), which is essential for high levels of MERS-CoV 
receptor activity. Importantly, introduction of the charged residue at 330 simultaneously destroys 
the glycosylation site, preventing us from testing whether the presence of the charged residue at 
330 can enhance mDPP4 receptor activity in the presence of a glycosylation site. However, we 
can remove the glycosylation site without introducing a charged residue with the mutation 
 
Figure 1.6: Glycosylation can act to dramatically reduce infection by MERS-CoV 
(A) HEK 293T cells were transfected with each DPP4 construct and infected with rMERS-CoV-
RFP at an MOI of 1 at ~18 h post-transfection. At ~24 hpi, cells were imaged. (B) Cells were 
transfected as in (A) and infected with rMERS-CoV-RFP at the following MOIs: hDPP4 and 
hDPP4 R336T, 0.001; no DPP4 and hDPP4 + gly, 0.1. At 24 hpi, cells were counted based on 
red fluorescence and values were normalized to an MOI of 0.1. Values represent 3 replicates. All 
mutants have levels that are statistically greater than no DPP4 and all other pairwise comparisons 
are also statistically significant (indicated by *, p < 0.05, Student’s t-test). (C) Western blot 
analysis for MERS nucleocapsid (N) protein, DPP4, and β-actin as a loading control. Western 
blot protocol follows Cockrell et al. 2014. From Peck et al. 2015b. 
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N328A, which disrupts the N of the NXT motif (Figures 1.5A and 1.5D). When we assessed the 
N328A mutant in the context of the A288L background we observed high levels of infection 
(Figure 1.7A) that are not statistically different from mDPP4 A288L, T330R (Figure 1.7B). Both 
glycosylation knockout mutants have levels that are statistically greater than mDPP4 but 
statistically less than hDPP4 (Figure 1.7B). All mutants containing the T330R or N328A 
mutation show a ~2.5 kDa downward shift in the Western Blot, consistent with the loss of 
glycosylation (Figure 1.7C). Importantly, surface staining for mDPP4 and hDPP4 signifies that 
 
Figure 1.7: Glycosylation is more important than charge in mediating MERS-CoV infection 
(A) Cells were transfected and infected following the protocol detailed in Figure 1.6A. Neither 
mDPP4 N328A, nor mDPP4 T330R can confer permissivity to MERS-CoV, however both result 
in strong levels of infection when coupled with A288L. (B) Red cell counts were calculated as in 
Figure 1.6B with the following MOIs: hDPP4, 0.001; mDPP4, mDPP4 288, mDPP4 328, 
mDPP4 330, no DPP4, 0.1; mDPP4 288, 328 and mDPP4 288, 330, 0.01. All DPP4 constructs 
are significantly greater than no DPP4 and mDPP4 (*, p < 0.05, Student’s t-test) and 
significantly less than hDPP4 (+, p < 0.05, Student’s t-test); however mDPP4 A288L, N328A 
and mDPP4 A288L, T330R are not statistically different from each other (n.s., p < 0.05, 
Student’s t-test).  (C) Western blot analysis for MERS nucleocapsid (N) protein, DPP4, and β-
actin as a loading control. Western blot protocol follows Cockrell et al. 2014. From Peck et al. 
2015b. 
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all derivatives of the DPP4 receptors are expressed at the cell surface and available to interact 
with the MERS-CoV RBD (Figure 1.8). Together, these results indicate that removal of the 
glycosylation site, rather than addition of the charged residue at position 330, is responsible for 
regulating the ability of MERS-CoV to utilize mDPP4 as a functional receptor. The secondary 
mutation, A288L, also plays an important role in MERS-CoV permissivity because high levels 
of infection are only seen when the glycosylation mutants are combined with the A288L 
substitution (Figures 1.7A and 1.7B). Together, this suggests that while glycosylation is an 
important barrier, its removal is not sufficient to permit infection in the absence of the A to L 
modification at position 288. Overall, glycosylation can act to block MERS-CoV infection, yet 
other determinants are also important for mediating permissivity. Further research will determine 
the relative contributions of these determinants and whether they act as a broader signature of 
permissivity among DPP4 orthologs. 
 
Figure 1.8: DPP4 construct expression in HEK 293T cells  
DPP4 and mutant variants are expressed on the surface of cells, visible by immunofluorescence 
(IFA). Cells were transfected as described in Figure 1.6A, fixed, and probed with primary goat-
anti-DPP4 polyclonal antibody (R&D Systems) at 1:50 and secondary donkey-anti-goat Alexa 
Fluor 488 (Life Technologies) at 1:500. Cells were imaged at 40X for DAPI (30 ms exposure) 
and DPP4 (160 ms exposure). From Peck et al. 2015b. 
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1.4 Removing glycosylation from mDPP4  
 The above experiments analyzed the removal of glycosylation from mDPP4 using PCR 
mutagenesis. Knockout of the glycosylation site was evaluated by Western blot, with a 
downward shift of the protein band by ~2.5 kDa indicating successful removal of the glycan. 
However, additional resources are available for removing (or preventing) the glycosylation of 
protein molecules. Tunicamycin acts by inhibiting the formation of N-linked glycans (Esko and 
Bertozzi 2009). PNGase F, on the other hand, acts to cleave the glycan from the amino terminus 
after formation (Mulloy et al. 2009). I tested both of these methods in order to determine whether 
the previously discovered phenotype, that removing glycosylation from mDPP4 can confer 
permissivity to MERS-CoV, could be recapitulated with various methods of glycan removal. 
One caveat to these experiments is that DPP4 is known to have many putative glycosylation 
sites. hDPP4, for example, has nine N-linked glycosylation sites throughout the molecule, eight 
of which are clustered to blades II through V of the β-propeller domain (Rasmussen et al. 2003). 
The presence of multiple glycosylation sites within DPP4 may cause the use of tunicamycin or 
PNGase F to be too disruptive for proper folding and function of the molecule. 
 HEK 293T cells were transfected with 3 µg of hDPP4 or mDPP4 using previous 
protocols. At ~2 hours post-transfection, 1 µg/mL of tunicamycin was added to the cells and 
incubated at 37 ºC for ~24 hours. Different amounts of tunicamycin are efficacious for various 
cell types (Esko and Bertozzi 2009); 1 ug/mL was chosen as a reasonable concentration after 
testing a range of 0 to 5 µg/mL. One set of cells was used for protein analysis; protein lysates 
were harvested using the previously detailed 1X RIPA buffer protocol and analyzed by Western 
blot (Figure 1.9A). A second set of cells was used for analysis of infection by rMERS-CoV-RFP 
(Figure 1.9B). The Western blot analysis shows a severe downward shift in the DPP4 bands after 
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tunicamycin treatment, suggesting successful inhibition of glycan formation (Figure 1.9A). 
However, the infection results show that mDPP4 does not gain permissivity to rMERS-CoV-RFP 
when glycosylation is inhibited and hDPP4 loses its ability to confer infection (Figure 1.9B). The 
ablation of permissivity in hDPP4 suggests that other glycosylation sites are critical to DPP4 
folding and/or function, specifically for MERS-CoV RBD interactions. The reduction in 
molecule size of both mDPP4 and hDPP4 suggests that they have a similar number of 
glycosylation sites and that the additional glycosylation sites in mDPP4 may also be crucial for 
proper functionality. These results rule out my ability to use tunicamycin in future glycosylation 
analysis experiments for DPP4.  
 
 
 
Figure 1.9: Tunicamycin treatment of DPP4 molecules 
(A) Western blot analysis of HEK 293T cells transfected with either mDPP4 or hDPP4 (fused to 
venus) and treated with 1 ug/mL tunicamycin (Tu) ~2 hours post-transfection. Protein lysates 
were harvested ~24 hours post-treatment with Tu. Shifted bands indicate the successful 
inhibition of glycosylation. Western blot protocol follows Figure 1.1 (Cockrell et al. 2014). (B) 
HEK 293T cells transfected with mDPP4 or hDPP4 and treated with Tu ~2 hours post-
transfection. Cells were infected with rMERS-CoV-RFP ~24 hours post-treatment with Tu and 
imaged ~24 hpi.  
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To test the efficacy of PNGase F, HEK 293T cells were transfected with 3 µg of hDPP4 
or mDPP4 following previously detailed protocols. At ~24 hours post-transfection, cells were 
washed twice with 1X PBS. PNGase F (NEB) was diluted in 1X PBS to final concentrations of 
0, 2500, and 5000 units/mL. Cells were incubated at 37 ºC for 1 hour and then rinsed twice with 
1X PBS. Protein lysates were then harvested using the previously describe 1X RIPA buffer 
protocol and analyzed by Western blot (Figure 1.10). Unfortunately, even at a concentration 
using 5000 units/mL, no downward shift in protein size is visible (Figure 1.10). This indicates 
that 1) the concentration of PNGase F may need to be higher, although this puts it outside of the 
range found to be effective for other proteins, or 2) the surface glycans on DPP4 do not meet the 
requirements needed for PNGase F to be effective. Namely, the enzyme requires at least one 
amino acid at both the amino and carboxyl terminus of the asparagine (N) in order for proper 
cleavage (Mulloy et al 2009). Additionally, the traditional PNGase F protocol treats proteins 
 
Figure 1.10: PNGase F treatment of DPP4 molecules 
Western blot analysis of HEK 293T cells transfected with either hDPP4 or mDPP4. At ~24 hours 
post-transfection, cells were washed and treated with 0 to 2500 units/mL of PNGase F at 37 ºC 
for 1 hour. Protein lysates were harvested ~1 hours post-treatment with PNGase F. Western blot 
protocol follows Figure 1.1 (Cockrell et al. 2014) with the top bands indicating DPP4 and the 
bottom bands indicating β-actin.  
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after they have been harvested from the cells. However, because I was interested in treated 
monolayers and testing for infection, I treated the cells directly. This protocol adjustment could 
also explain the failure of PNGase F to remove glycans. Because of the lack of evidence for 
glycan removal (protein size shifting via Western blot) after treatment (Figure 1.10), PNGase F 
was not used in subsequent experiments on DPP4 glycosylation and MERS-CoV permissivity. 
The importance of glycosylation in the interactions between coronaviruses and host-cell 
receptors has previously been recognized. For example, the introduction of a glycosylation site 
into human APN prevents HCoV-229E from utilizing it as a receptor (Wentworth and Holmes 
2001). For MERS-CoV, it is possible that glycosylation can act as a broader determinant of 
DPP4-mediated host range, since other nonpermissive hosts (i.e. ferrets, hamsters) also have a 
non-conserved glycosylation site in the region of DPP4 that interacts with the MERS-RBD 
(Figure 1.5A). In the context of a small animal model, the presence of the glycosylation site at 
330 may sterically hinder multiple interacting residues between the MERS-CoV RBD and 
mDPP4, complicating the generation of a mouse-adapted strain. Therefore, it may be necessary 
to partially, or fully, humanize mDPP4 to achieve in vivo MERS-CoV replication. Additionally, 
the finding that changes in both blades of mDPP4 are crucial for mediating permissivity to 
MERS-CoV (Figure 1.7A) has two major implications. First, it may help inform future studies in 
other nonpermissive hosts. Second, it suggests that circulating MERS-like coronaviruses cannot 
expand their host range into mice and possibly other rodent species with just one change. Rather, 
extensive remodeling of the MERS-CoV RBD is likely required for it to successfully utilize 
nonpermissive DPP4 orthologs as receptors, especially if glycosylation acts to block infection in 
these alternate species. Presumably, the modifications that would allow the MERS-CoV RBD to 
utilize mDPP4 and other orthologs would likely attenuate or even ablate its ability to utilize 
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hDPP4. Overall, by understanding the biochemical determinants that mediate MERS-CoV 
utilization of DPP4 orthologs, we can begin to characterize the selective pressures leading up to 
host-range expansion events, with the broader goal of being able to predict future emergences.  
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CHAPTER 2: BIOCHEMICAL DETERMINANTS OF DPP4 ORTHOLOG PERMISSIVITY 
TO MERS-CORONAVIRUS 
2.1 Introduction 
Among viruses for which the host receptor has been identified, there is an association 
between host range and phylogenetic conservation of that receptor (Woolhouse 2002). This 
result is consistent with previous species-level studies that have shown that the more 
phylogenetically related two species are, the more likely it is that a virus will be able to jump 
between them (deFilippis and Villarreal 2000). These observations confirm that the host receptor 
is a primary determinant of host range expansion and also that receptor conservation can 
potentially act as a screen to identify viruses that are likely to jump into humans. 
The link between DPP4 sequence conservation across species and permissivity to MERS-
CoV infection, however, is not obvious. While only a small subset of species have been tested in 
vitro (Muller et al. 2012, de Wit et al. 2013a, de Wit et al. 2013b, Ohnuma et al. 2013, Barlan et 
al. 2014, Cockrell et al. 2014, Coleman et al. 2014, Eckerle et al. 2014, Falzarano et al. 2014, 
Raj et al. 2014, van Dormalen et al. 2014), there is no clear phylogenetic clustering of 
permissive and nonpermissive hosts when analyzing the DPP4 gene tree (Cui et al. 2013, Peck et 
al. 2015c). The lack of a clear pattern of permissivity among closely-related DPP4 genes 
suggests that other aspects of DPP4 may be more important than simply linear amino acid 
sequence, such as structural similarity or conservation of post-translational modifications (e.g. 
glycosylation). Alternatively, or in addition, receptor-independent host restriction mechanisms 
may operate in some species. 
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To understand the interactions between the MERS-CoV RBD and DPP4 and to better 
characterize the host range expansion events of MERS-CoV, both past and potential, I examined 
the permissivity of various DPP4 orthologs. After establishing the characteristics and 
permissivity of these orthologs, I determined whether there was a detectable broad signature of 
permissivity. Primarily, do all nonpermissive species block MERS-CoV infection using the same 
mechanisms? Because phylogenetic relatedness did not yield a signal (Cui et al. 2013, Peck et al. 
2015c), and analyzing the sequences at previously identified key RBD residues (Cockrell et al. 
2014) did not yield any obvious hypotheses (Table 1), I turned to the results found in Chapter 1. 
Based on the discovery that glycosylation is an important barrier to MERS-CoV infection, I 
noticed that some nonpermissive species also have glycosylation sites near the site observed in 
mDPP4 (Figure 1.5A). Thus, I tested whether glycosylation acts to block MERS-CoV infection 
in other nonpermissive species before investigating alternate determinants. 
2.2 Determine the role of glycosylation in additional DPP4 orthologs 
First, I validated the panel of DPP4 constructs I had generated by confirming the 
permissive or nonpermissive nature of various species orthologs. While hDPP4 and mDPP4 were 
 282 288 289 330 340 
Human T L I R I 
Bat T L T K I 
Camel V L I R I 
Mouse P A R T V 
Guinea Pig A I T G T 
Ferret T S T S T 
Hamster T L T T V 
 
Table 1: Amino acid identities at five DPP4 ortholog residues important for MERS-CoV binding 
Amino acid identities at the five residues identified to be important for mediating MERS-CoV 
permissivity in the context of mDPP4 (Cockrell et al. 2014). Residue numbering is relative to 
mDPP4. Permissive and nonpermissive species are indicated by black and red text, respectively.  
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obtained as a complete plasmid, I generated the remaining DPP4 orthologs using Gibson 
assembly (Gibson et al. 2009). This method employs an in vitro recombination method to allow 
for the rapid and financially tractable assembly of multiple DPP4 constructs.  
Following previous methods, I transfected 3 µg of each DPP4 ortholog into HEK 293T cells. At 
~24 hours post-transfection, I infected the cells with rMERS-CoV-RFP at an MOI of 1. At ~24 
hours post-infection, I visualized the cells to determine whether they were permissive to MERS-
CoV. As expected, human, bat, and camel DPP4 molecules are permissive to MERS-CoV 
infection while mouse, ferret, guinea pig, and hamster are not (Figure 2.1). Although previous 
work (Cockrell et al. 2014) generated data that was used to develop a mouse model for MERS-
CoV, understanding why ferret, hamster, and guinea pig cannot be infected could help create a 
secondary option for studying MERS-CoV pathogenesis. 
 
  
Figure 2.1: Permissivity of DPP4 orthologs to MERS-CoV 
Seven DPP4 orthologs were tested for their ability to support infection by rMERS-CoV-RFP. 
DPP4 constructs were transfected into HEK 293T cells and infected at an MOI of 1 ~24 hours 
post-transfection. Cells were imaged for fluorescence ~24 hpi. hDPP4, human DPP4; cDPP4, 
camel DPP4; bDPP4, bat DPP4; mDPP4, mouse DPP4; fDPP4, ferret DPP4; haDPP4, hamster 
DPP4; gpDPP4, guinea pig DPP4. 
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Aligning the sequences of the permissive and nonpermissive species in a region crucial to 
MERS-CoV binding reveals the presence of a glycosylation site in hamster DPP4 (haDPP4), 
ferret DPP4 (fDPP4), and guinea pig DPP4 (gpDPP4) molecules (Figure 2.2A). The 
glycosylation site in hamster is identical to that in mouse, suggesting that it may interact with the 
MERS-CoV RBD in a similar way. The glycosylation site in fDPP4 is slightly upstream, and the 
glycosylation site in gpDPP4 is slightly downstream (Figure 2.2A). However, the latter is shared 
by bDPP4 (sequence from species Pipistrellus pipistrelle), suggesting that it might not play as 
important of a role in blocking infection unless there is a gpDPP4-specific structural effect. 
 
Figure 2.2: Sequence and structural comparison of nonpermissive DPP4 orthologs 
(A) Sequence alignment of permissive (human, camel, bat; blue) and nonpermissive (mouse, 
ferret, hamster, guinea pig; red) DPP4 amino acid sequences. Residue 330 is numbered relative 
to mDPP4. Boxes represent glycosylation sites that are either unique to nonpermissive species 
(black) or shared with a permissive species (gray). (B) Structural comparison of threaded 
molecules (Zhang 2008) fDPP4 (green), haDPP4 (blue), and gpDPP4 (purple) overlaid on 
hDPP4 (yellow) complexed with the MERS-CoV RBD (red) (PDB code 4L72).  
40 
The crystal structures for fDPP4, haDPP4, and gpDPP4 have not yet been solved. 
Utilizing the same threading technique as in Chapter 1, I generated predicted structures for each 
of these proteins using I-TASSER (Zhang 2008). Overlaying the structures with hDPP4 shows 
that they are predicted to have highly similar structural backbones (Figure 2.2B). Again, 
maintaining awareness that the structures are predictions, the RMS scores obtained for fDPP4, 
haDPP4 and gpDPP4 overlaid with hDPP4 are 0.616, 0.378, and 0.604, respectively. This can be 
compared to amino acid sequence identity values of 88%, 85%, and 87%, respectively. From 
these computational results, haDPP4 is predicted to be the most structurally similar to hDPP4 
and may be the best option for an alternate transgenic animal model. 
 Based on my previous discovery that glycosylation plays an important role in blocking 
MERS-CoV, I knocked out the glycosylation sites in each of these species using PCR 
mutagenesis. Each of these knockout mutations changed the N of the glycosylation NXT (or 
NXS) motif to an alanine and are designated as “-gly” in subsequent figures. Following previous 
methods, 3 µg of each DPP4 construct was transfected into HEK 293T cells. At ~24 hours post-
transfection, cells were infected with rMERS-CoV-RFP at an MOI of 1. At ~24 hours post-
infection, cells were imaged and red fluorescence analyzed as a readout of infection. My results 
show that removing glycosylation from these three DPP4 orthologs did not result in an increase 
in infection (Figure 2.3A). The amount of infection that was supported by all three glycosylation 
knockout molecules was equivalent to their respective wildtype molecules. The glycosylation, 
and subsequent removal, of each of these sites was confirmed by Western blot analysis (Figure 
2.3B), following previous protocols (Peck et al. 2015b). 
 Upon further inspection of the haDPP4 sequence, I noticed a putative glycosylation site 
upstream of the previously identified one (Figure 2.2A). The motif NKT (starting at residue 329) 
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is directly upstream from the previously studied NLT (starting at residue 332) glycosylation site. 
As a test to determine whether this site affected permissivity, particularly because the equivalent 
288 residue found to be important in mice shares the human amino acid identity in haDPP4, I 
generated constructs that mutated the N of the NKT motif using PCR mutagenesis, both singly 
and in combination with the NLT glycosylation knockout. Transfecting the haDPP4 
glycosylation variants into HEK 293Ts and infecting with rMERS-CoV-RFP revealed that 
mutating this additional glycosylation site had no impact on infection (Figure 2.4). Furthermore, 
mutating both of the glycosylation sites together did not have any impact on infection levels 
 
 
Figure 2.3: DPP4 ortholog glycosylation knockout mutants 
(A) Neither wildtype nor glycosylation knockout DPP4 molecules for ferret (fDPP4), hamster 
(haDPP4), nor guinea pig (gpDPP4) support infection by MERS-CoV. (B) Successful removal of 
glycosylation is supported by a ~2.5 kDa downward shift in protein analysis via Western blot. 
Top blot represents DPP4 and the bottom blot represents β-actin as a control. Western blot 
protocol follows Peck et al. 2015b. 
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(Figure 2.4). It is possible that the NKT motif is not actually glycosylated; my next step is to 
validate glycosylation by Western blot before drawing further conclusions. 
Whereas fDPP4 and haDPP4 did not share their glycosylation sites with permissive 
molecules, gpDPP4 shared its downstream glycosylation site with bDPP4. Due to this similarity, 
I knocked out the glycosylation site in bDPP4 to determine 1) whether it was actually 
glycosylated and 2) its impact on the permissivity of bDPP4. Using PCR mutagenesis to mutate 
the N of the NXS motif to an alanine, I followed previous protocols to express the bDPP4 mutant 
in HEK 293T cells and visualized the cells ~24 hours post-infection. My results show that 
removing glycosylation from bDPP4 has no detectable difference on its ability to support 
MERS-CoV infection (Figure 2.5). My next step is to perform a Western blot in order to 
 
Figure 2.4: Glycosylation knockout panel in haDPP4 
haDPP4 has two glycosylation sites near the site identified as important for mediating MERS-
CoV permissivity in mDPP4. Knocking out the NKT (starting at residue 329) or the NLT 
(starting at residue 332) motif, or both in combination, has no impact on MERS-CoV 
permissivity. Mutating the residues to either alanines or the equivalent amino acid identity in 
hDPP4 (D or S, respectively) also shows no impact. 
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determine whether the bDPP4 molecule is actually glycosylated or whether the NXS represents a 
sequence motif that is not, in actuality, glycosylated in the final molecule. 
Overall, glycosylation is not the only determinant that mediates MERS-CoV infection in 
nonpermissive DPP4 orthologs. This is particularly surprising in the case of haDPP4; this protein 
not only has a glycosylation site in the same location as mDPP4 (Figure 2.2A), but the secondary 
residue that was identified to be important for mDPP4 (residue 288) in haDPP4 is the same 
amino acid identity as hDPP4 (Table 1). Based on this observation, while removing 
glycosylation may be a substantial component of permitting infection in these DPP4 orthologs, 
other determinants clearly play an important role.  
The importance of glycosylation in blocking MERS-CoV infection may vary between 
species. To gain a better intuition about the extent of glycosylation among DPP4 orthologs, I 
 
Figure 2.5 Guinea pig and bat DPP4 glycosylation knockout mutants 
Bat and guinea pig DPP4 share the same glycosylation site downstream of the site identified to 
be important in mDPP4 (Figure 2.2A). Removing the glycosylation site from bDPP4 shows no 
decrease in infection while removing glycosylation from gpDPP4 shows no increase in infection. 
44 
constructed a phylogenetic tree of a subset of full-length DPP4 protein sequences (Figure 2.6). 
Retrieving the sequences from GenBank, I used MAFFT to align the amino acid sequences 
(Katoh et al. 2002). The phylogenetic tree was generated using maximum likelihood with the 
PhyML package (Guindon et al. 2010) and visualized using EvolView (Zhang et al. 2012). In the 
tree, shaded colors indicate the general organism group that each species belongs to - blue: 
reptiles and amphibians; green: avian species; orange: other mammals; red: Chiroptera (bats); 
purple: ungulates; gray: rodents; pink: primates (Figure 2.6).  The DPP4 protein tree is slightly 
discordant with the species tree, notably with the horse and African savanna elephant DPP4 
sequences not clustering with other ungulate (purple) orthologs. 
Plotted adjacent to the phylogenetic tree are glycosylation sites that are either upstream 
(column 1), at the same site (column 2), or downstream (column 3) of the glycosylation site that 
is present in mDPP4 (residues 328-330). Based on this tree, only eight other species have 
putative glycosylation sites at the same location as in mDPP4; the majority of these are present in 
the rodent (gray) group, however two are present within the Chiroptera group (black flying fox 
and large flying fox) (Figure 2.6). Permissivity data is indicated in the far right column, with 
green squares indicating permissive species and red squares indicating nonpermissive species, 
based on either in vitro or in vivo data (de Wit et al. 2013a, Barlan et al. 2014, Eckerle et al. 
2014, Cockrell et al. 2014, Coleman et al. 2014, Raj et al. 2014, van Doremalen et al. 2014). The 
small number of data points for species makes it difficult to map potential shifts in permissivity. 
However, a few interesting observations emerge. First, all non- human primates lack 
glycosylation sites near residue 330 (equivalent residue 336 in humans) (Figure 2.6). Current 
data would postulate that all non-human primates are permissive to MERS-CoV infection, but 
testing this hypothesis in vitro would help reveal whether any of these orthologs are 
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Figure 2.6: DPP4 protein 
phylogenetic tree 
DPP4 phylogenetic tree based on 
amino acid sequences. Shaded 
colors indicate the group each 
species falls in. Blue: reptiles and 
amphibians; Green: avian 
species; Orange: other mammals; 
Red: Chiroptera (bats); Purple: 
ungulates; Gray: rodents; Pink: 
primates. Colored circles to the 
right of the species names 
indicate whether the sequence 
has a glycosylation site upstream 
(first column), at the same site 
(second column), or downstream 
(third column) of the NXT 
glycosylation site in mDPP4 
(residues 332-334). Numbers 
inside the circle designate how 
many amino acids upstream (or 
downstream) the N of the NXT 
or NXS putative glycosylation 
site is. For the second column, a 
1 indicates that there is a 
glycosylation site at the same 
location as in mDPP4. Squares in 
the rightmost column indicate 
permissive (green) or non-
permissive (red) species, as 
determined from either in vivo or 
in vitro studies. See Appendix B 
for species Latin names and 
NCBI accession numbers. 
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nonpermissive. If so, a separate mechanism from glycosylation at our location of interest would 
be responsible for blocking MERS-CoV infection. Second, whereas other permissive DPP4 
orthologs have glyocyslation sites in this region (horse and common pipistrelle DPP4), of note is 
the lack of a glycosylation site in the nonpermissive domestic pig, sheep, and cattle DPP4 
molecules (Figure 2.6). This suggests that glycosylation in this region is not the primary 
explanation for why these species do not support MERS-CoV infection. Follow-up studies could 
explore the mechanism of nonpermissivity in this species specifically, and whether or not it lies 
at the level of the receptor. Third, glycosylation sites in the designated region are prevalent in 
rodents, other mammals, and avian species (Figure 2.6). The diversity of glycosylation profiles 
suggests a lack of strong conservation of the site seen in mDPP4. Further research to determine 
whether these other orthologs are permissive can help elucidate whether this region plays a 
broader role in the MERS-CoV infection phenotype. In general, while some trends are seen when 
looking at the glycosylation profile across many species (e.g. upstream glycosylation sites in the 
other mammal (orange) group), more data on species permissivity will help determine whether 
DPP4 phylogenetic relationships can help inform receptor-binding dynamics. 
2.3 Identify key mutations and determinants of DPP4 ortholog permissivity to MERS-CoV 
infection 
 The mDPP4 data suggest that two mutations are necessary to support MERS-CoV 
infection, one on each blade of the DPP4 molecule (Cockrell et al. 2014, Peck et al. 2015b). The 
mechanisms of mDPP4 permissivity included stabilizing a hydrophobic core and removing a 
glycosylation site (Peck et al. 2015b). However, the simplicity of this determinant does not carry 
over; haDPP4 has the same amino acid as hDPP4 at the residue that stabilizes the MERS-CoV 
RBD hydrophobic core, and yet knocking out glycosylation does not confer infection (Figure 
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2.3A). This suggests other determinants are important for conferring permissivity in these other 
molecules. 
Other groups have introduced single point mutations in both haDPP4 and fDPP4 to try to 
instigate permissivity (Raj et al. 2014, van Doremalen et al. 2016). For haDPP4, other studies 
found that a minimum of five amino acid mutations allowed the molecule to support MERS-CoV 
infection (van Doremalen et al. 2016). Focusing on the idea that changes in both blades IV and V 
of DPP4 are required to confer infection in the context of mDPP4, I constructed chimeric fDPP4 
and haDPP4 molecules that made substantial changes on both blades. Using overlap PCR, I 
constructed a chimeric fDPP4 that swaps out 16 residues on blade V and 11 residues on blade IV 
to the equivalent human amino acid identities, indicated by their starting residues of 278 and 
331, respectively. Transfecting 3 µg of the chimeric fDPP4 constructs into HEK 293T cells and 
infecting with rMERS-CoV-RFP (MOI 1) at ~24 hours post-transfection yielded results that 
were imaged ~24 hours post-infection. Results show that while the single glycosylation knockout 
mutant did not show an increase in infection, the combination of 27 amino acid changes on 
blades IV and V show a dramatic increase in infection (Figure 2.7A). Western blot analysis 
shows that each DPP4 variant is being highly expressed; however, because of the large number 
of amino acid changes present in each mutant, a downward shift in the protein band is visible for 
each construct (fDPP4 (278), fDPP4 –gly, fDPP4 (278)(331)) (Figure 2.7C), obscuring the usual 
signal representative of glycan removal.  
To further investigate the contributions of the 27 swapped amino acids in fDPP4 that 
supported infection, I took a subset of amino acid changes on each blade and made subsets  
of point mutations inside the larger block (indicated by ‘snp’). These mutations were selected 
based on whether the amino acids were found in permissive or nonpermissive species; amino 
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acids in fDPP4 that could be found in a permissive species were not included in the fine-tuning 
mutation sets. 278snp includes the mutations E285Q, D290A, A291S, and S293L. 330snp 
includes the mutations N330D, N331E, and D332S. 334snp includes the mutations N334G, 
S335R, and R337N. 338snp includes the mutations K338C, P339L, and E340V (Figure 2.8). 
Each construct was transfected into HEK 293T cells following previous protocols and infected 
with rMERS-CoV-RDP at an MOI of 1. Results show that all combinations of mutants show 
 
Figure 2.7: Many amino acid changes are required to make fDPP4 and haDPP4 permissive to 
MERS-CoV infection 
(A) Removing glycosylation on its own does not confer permissivity to fDPP4. However, 
introducing a set of amino acid changes on blade IV (starting at residue 331) and blade V 
(starting at residue 278) allow fDPP4 to support MERS-CoV infection (fDPP4 (278)(331)). 
Sequences show the alignment between hDPP4 and fDPP4 with the blue boxes indicating the 
amino acids that were swapped from hDPP4 into fDPP4. Note that fDPP4 –gly is a negative 
control and only includes the single point mutation N332A. (B) Removing glycosylation on its 
own does not confer permissivity to haDPP4. However, combining three amino acid changes on 
blade V (starting at residue 291) with the glycosylation knockout mutant on blade IV (N332A) 
results in high levels of MERS-CoV infection. Sequences show the alignment between hDPP4 
and haDPP4 with the blue boxes indicating the amino acids that were swapped from hDPP4 into 
haDPP4. (C) Western blot analysis of fDPP4 and haDPP4 and designated variants for DPP4 and 
β-actin expression. Western blot protocol follows Peck et al. 2015b. 
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lower levels of infection compared to when both blocks (278) and (331) are included together 
(Figure 2.8). Interestingly, the mutants fDPP4 (278), 334snp and fDPP4 (278), 338snp show 
increased levels of infection compared to all other combination sets (Figure 2.8). This suggests 
that 1) the (278) block is an important determinant and cannot be recapitulated with a subset of 
the four selected amino acids and 2) infection is more robust to amino acid changes on blade IV. 
 
Figure 2.8: Fine-tune mapping of fDPP4 determinants for MERS-CoV permissivity 
Sets of mutations were made in fDPP4 for fine-tune mapping of MERS-CoV permissivity 
determinants. The table indicates which combination of hDPP4 amino acid identities were 
introduced into fDPP4 on blade V (rows) or blade IV (columns). Blue boxes around the 
sequences indicate blocks of amino acid swaps designated by (278) and (331). 278snp includes 
four amino acid swaps on blade V designated by the red asterisks. 330snp, 334snp, and 338snp 
each include three amino acid swaps on blade IV indicated by the green, purple, and orange 
asterisks, respectively. 
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In fact, the lack of increased infection for fDPP4 (278), 330snp (Figure 2.8) suggests that our 
hypothesis surrounding glycosylation as an important barrier may not be as applicable to fDPP4. 
The 330snp subset removes the glycosylation site while the 334snp and 338snp amino acid 
changes do not. However, we cannot rule out that the 334snp and 338snp amino acid mutations 
alter the structure of fDPP4 in a way that shifts the glycosylation site and allows proper binding 
by MERS-CoV. Overall, the determinants that would allow fDPP4 to fully support MERS-CoV 
infection are complex and require further investigation to fully understand. 
 In the context of haDPP4, fewer amino acid changes can result in a dramatic increase in 
the infection levels (Figure 2.7B). Compared to fDPP4, which I found to require 27 mutations 
(possibly less), haDPP4 can support high levels of infection with just four mutations: E291A, 
V293M, T295I, and N332A. The first three are present on blade V while the fourth is on IV and 
removes the glycosylation site (Figure 2.7B). As with fDPP4, these residues were selected based 
on examining amino acids that were not present in permissive DPP4 orthologs. The four 
identified mutations overlap with previous studies that found five amino acid changes in haDPP4 
were required for high levels of MERS-CoV infection (van Doremalen et al. 2016). To 
determine whether fewer mutations could recapitulate the results seen with all four, I used PCR 
mutagenesis to make a set of the mutations individually and in combination with the 
glycosylation knockout (N332A, designated as ‘-gly’). 
 Following previous protocols, I transfected each haDPP4 construct into HEK 293T cells 
and infected with rMERS-CoV-RFP at an MOI of 1. Visualizing at ~24 hours post-infection 
reveals that no smaller set of amino acid mutations can fully recapitulate the increased levels of 
infection seen by all four combined (Figure 2.9). Although the construct haDPP4 293, -gly was 
not tested, it is unlikely that it would result in high levels of infection. This is supported by the 
51 
work by van Doremalen et al. (2016) which demonstrated that less than five amino acid changes 
were unable to confer high permissivity to MERS-CoV. Of these, residue 295 overlaps with the 
results found here, while residue 336 removes a glycosylation site, functionally achieving the 
same as the 334 mutation presented here (Table 2). Our conclusions show that while 
glycosylation is likely an important barrier to MERS-CoV infection, there are additional 
determinants on blade V that also play a crucial role. 
Comparing the data we have so far on the residues that are important for mediating 
permissivity in hDPP4, mDPP4, haDPP4, it is difficult to discern an obvious pattern (Table 2). 
The only clear trend is that at least one change is required on both blades IV and V of DPP4. 
This indicates that there are two key points of interaction between DPP4 and the MERS-CoV 
RBD that are important for allowing the virus to utilize a new species receptor. Further 
understanding of the host range expansion of MERS-CoV will come with further data on which 
mutations can confer permissivity to DPP4 receptors of currently nonpermissive species. 
 
Figure 2.9: Fine-tune mapping of haDPP4 permissivity to MERS-CoV 
Sets of mutations in haDPP4 in order to map determinants of permissivity to MERS-CoV 
infection. Mutations, indicated by residue numbers are as follows: E291A; T295I; (291): E291A, 
V293M, T295I; -gly: N332A (see Figure 2.7B). 
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Additionally, solving the crystal structures of nonpermissive DPP4 orthologs will reveal the 
specific interactions between these molecules and MERS-CoV, particularly what prevents 
MERS-CoV from successfully utilizing these molecules are functional receptors. The inability to 
identify a small number of changes that confer permissivity to DPP4 orthologs substantiates the 
earlier hypothesis that extensive remodeling of the MERS-CoV RBD would be required for the 
virus to infect these nonpermissive species, predominantly in order to overcome the barrier of 
glycosylation. While this result indicates that generating a virus that can infect these species will 
be difficult, it also suggests that the emergence of MERS-like coronaviruses into these species in 
a natural setting is unlikely. Additionally, the generation of a transgenic model in these other 
species is intractable due to the number of mutations each DPP4 would require. 
2.4 Adaptation to alternate receptor molecules 
In addition to considering the adaptation of MERS-CoV to nonpermissive DPP4 orthologs, we 
can also consider the possibility of MERS-CoV gaining the ability to utilize a new receptor. 
Ortholog Important residues Source 
Human 
DPP4 
267   294 295   336   Song et al. 2014 
Mouse 
DPP4 
   294    336*   Cockrell et al. 2014 
Hamster 
DPP4 
 291   295   336* 341 346 
van Doremalen et al. 
2014, 2016 
Hamster 
DPP4 
  293  295 297 334*    Peck et al. in prep 
 
Table 2: Residues identified to be important for MERS-CoV permissivity 
Experimental studies and the residues that have been identified as important for mediating 
permissivity to MERS-CoV among various DPP4 orthologs in vitro. All residues are relative to 
the aligning residue in hDPP4. Residues are either on blade IV (blue shading) or on blade V 
(gray shading). * indicates residues that knock out a glycosylation site in the mouse and hamster 
DPP4 molecules. Modified from Peck et al. 2015c. 
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Experimental evidence has shown that coronaviruses can adapt to an alternate receptor; MHV 
can shift from using its natural receptor CEACAM1a, to using heparan sulfate to enter the host 
cell in persistently infected cell cultures (de Haan et al. 2005). MERS-CoV could potentially 
evolve to utilize another dipeptidyl peptidase family member, such as DPP8, DPP9, or fibroblast 
activation protein (FAP). All three of these proteins are predicted to share high structural 
homology with DPP4 (Figure 2.10), despite low amino acid sequence identity (22%, 20%, and 
52%, respectively). FAP appears to be the most likely candidate with the highest sequence and 
structural homology (Figure 2.10); FAP can also be expressed on the surface of cells, particularly 
at sites of tissue remodeling (Levy et al. 1999). While only some of the key residues identified in 
DPP4 studies match the amino acid identities and/or properties of FAP (Figure 2.10D), it could 
still act as a candidate for MERS-CoV adaptation. This shift in receptor usage could, for 
example, result from increased selective pressure following a reduction in expression of DPP4. 
Reduction in expression has been shown to occur in vitro where persistent MERS-CoV infection 
induces downregulation of DPP4 expression in bat cells (Cai et al. 2014). Additionally, selection 
for an alternate receptor could come from therapeutics that block DPP4 from being bound by the 
virus. While the use of antibodies against DPP4 is impractical due to the importance of DPP4 in 
other roles (Boonacker and van Noorden 2003), the administration of soluble DPP4 to prevent 
cell entry has been proposed (Xia et al. 2014) with results showing that soluble DPP4 can reduce 
and even block infection of cells by a pseudotyped MERS-CoV (Raj et al. 2013, Wang et al. 
2013). Further experiments should be considered to determine whether selection imposed by 
reduced DPP4 expression or DPP4-based therapeutics would drive MERS-CoV to utilize an 
alternate receptor. 
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 To investigate whether FAP can support MERS-CoV infection as a backbone molecule, I 
created a chimeric protein that swaps the region of hDPP4 that interacts with the MERS-CoV 
RBD into the FAP molecule (residues 279-343, numbering relative to FAP) (Figure 2.11B) using 
overlap extension PCR. The chimeric FAP molecule (FAP (279)) was then transfected into HEK 
293T cells following previously detailed protocols. At ~24 hours post-transfection, cells were 
infected with rMERS-CoV-RFP at an MOI of 1. At ~24 hours post-infection, cells were imaged 
with red fluorescence as a readout of infection.  
Results show that swapping the region of hDPP4 that interacts with MERS-CoV into the 
FAP backbone does allow for increased infection of the nonpermissive protein (Figure 2.11A). 
 
Figure 2.10: DPP4 family members 
(A) PyMOL visualization of crystal structures of human DPP4 (green, PDB code 4L72, chain A) 
aligned structurally to DPP8 (blue), (B) DPP9 (orange), or (C) FAP (magenta, PDB code 1Z68). 
DPP8 and DPP9 protein sequences were threaded using I-TASSER (Zhang 2008) to generate 
predicted structures. Alignment with DPP4 yields RMS values of 3.34 for DPP8, 3.41 for DPP9, 
and 0.782 for FAP calculated using PyMOL. (D) Key residues identified in mutagenesis studies 
with DPP4 orthologs (see Table 2) for permissive DPP4 orthologs and FAP. From Peck et al. 
2015c. 
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However, the increase in infection is slight and requires quantification before any 
conclusions can be drawn. Additionally, during the cloning procedure, three amino acid 
identities in the final FAP (279) product did not faithfully match hDPP4 (Figure 2.11A, red box). 
Thus, the next step is to fix this error and determine whether the correct product yields higher 
levels of permissivity. Additionally, IFA should be performed to determine whether FAP is 
being successfully expressed on the surface of the cells. As noted above, FAP is expressed on the 
cell surface primarily during tissue remodeling (Levy et al. 1999). Thus, some additional 
activation component may be required to properly express FAP on the cell surface and evaluate 
the ability of MERS-CoV to utilize it as a functional receptor. Regardless of the troubleshooting 
that needs to take place to solidify these conclusions, the increase in infection seen when FAP is 
utilized as a backbone (Figure 2.11A), although small, raises the question of whether MERS-
CoV could adapt to utilize FAP as an entry receptor. Extra care should be taken during the 
design of MERS-CoV therapeutics that are based on receptor targeting or interference. 
 
Figure 2.11: FAP as a backbone for supporting MERS-CoV infection 
(A) HEK 293T cells were transfected with hDPP4, FAP, or FAP (279). At ~24 hours post-
transfection, cells were infected with rMERS-CoV-RFP at an MOI of 1. Cells were imaged ~24 
hpi. (B) Sequences of hDPP4, FAP (279), and FAP. FAP (279) uses the FAP sequence as a 
backbone, but swaps in the hDPP4 amino acid identities for residues 279-343 (residues 
numbered relative to FAP). This region interacts with the MERS-CoV RBD during infection. 
Three amino acids were not swapped during cloning (red box), making this an imperfect replica 
of the hDPP4 binding interface.  
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Because the bat coronavirus BtCoV-HKU4 also utilizes DPP4 as an entry receptor, we 
can compare its RBD to that of MERS-CoV to determine whether it might show the same 
infection profile (and concerns) as MERS-CoV. The spike proteins of MERS-CoV and BtCoV-
HKU4 show 67% amino acid identity (accession numbers AHX00731.1 and YP_001039953.1, 
aligned using Vector NTI). MERS-CoV RBD residues important for facilitating the interaction 
between the virus and DPP4 include L506, W553, and V555 which form a hydrophobic core that 
interacts with hDPP4 residue L294 (Figure 2.12A), and RBD residue Y499 which engages the 
hDPP4 residue R336 (Wang et al. 2013). The amino acid identities at these locations in the RBD 
are partially conserved in BtCoV-HKU4 (Y503, L510, L558, I560) (Figures 2.12B, 2.12C), 
suggesting that utilization of hDPP4 and bDPP4 is robust to variation for some of these key 
interactions. Further studies can determine whether or not this characteristic is sufficient to allow 
BtCoV-HKU4 to utilize other host species receptors with the same efficiency as MERS-CoV, or 
whether BtCoV-HKU4 has the potential to emerge into the human population in the future.  
Based on the barrier of glycosylation in mDPP4 (Figure 1.7), it seems unlikely that BtCoV-
HKU4 is able to utilize mDPP4 as a functional receptor. BtCoV-HKU4 and MERS-CoV share 
the conserved Y499 residue that, probably, introduces steric hindrance into the binding 
interaction if a glycan is present at the R336 residue in DPP4 (Figure 2.12A). Unfortunately, the 
lack of a tissue culture system for BtCoV-HKU4 prevents easily testing its ability to infect the 
panel of mDPP4 variants generated above. Previous work done on BtCoV-HKU4 entry has had 
to utilize a BtCoV-HKU4-spike pseudovirus system (Yang et al. 2014), with potential noise in 
how accurately this recapitulates a wildtype infection. Potential solutions include introducing the 
BtCoV-HKU4 spike protein into the background of a closely related virus (e.g. BtCoV-HKU5) 
in order to test its host range and receptor interaction dynamics.  Additionally, it seems likely 
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that further metagenomics studies will reveal clusters of MERS-like group 2c strains that are 
more closely related to either BtCoV-HKU4 or MERS-CoV (Figure 0.2), which also utilize 
DPP4 receptors for entry. Thus, the structural mechanisms regulating DPP4 species-specificity 
and usage will become more clear over the next few years. 
 
Figure 2.12: Comparison of BtCoV-HKU4 and MERS-CoV RBD 
(A) Human DPP4 (green) bound to the MERS-CoV RBD (pink) (PDB code 4L72) overlaid by 
hDPP4 bound to the BtCoV-HKU4 RBD (yellow) (PDB code 4QZV). DPP4 residues 294 and 
336 (black) have been identified as important in the interactions with MERS-CoV. (B) MERS-
CoV (pink/purple) and BtCoV-HKU4 (yellow/orange) are partially conserved at the residues of 
the RBD that interact with hDPP4: 499, 506, 553, and 555. (C) GeneDoc alignment of part of the 
MERS-CoV and BtCoV-HKU4 RBDs. Arrows point to the RBD residues that interact with 
hDPP4. Numbers relative to MERS-CoV. Structures visualized using PyMOL. From Peck et al. 
2015c. 
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CHAPTER 3: MOUSE-ADAPTATION OF MERS-CORONAVIRUS 
3.1 Introduction 
Coronaviruses can infect over 20 different species and have undergone cross-species 
transmission into new species multiple times over the course of their evolutionary history. For 
example, the first human coronavirus that we know of was introduced into humans ~800 years 
ago and five other host range expansion events have been documented since then. Presently, 
what factors drive viral host range expansion is not well known. Changing habitats and the 
geographic expansion of humans into zoonotic territories may increase the probability of viruses 
achieving the needed exposure to accomplish a host range expansion (deFillippis and Villareal 
2000). However, because coronaviruses can infect such a diverse number of species, it may be 
possible that coronaviruses, specifically, have biological characteristics that make them more 
likely to infect new species compared to other viruses. No concrete evidence has surfaced to 
support this claim, but by understanding the recent expansion of SARS-CoV and MERS-CoV, 
we may gain some insight into whether coronaviruses are more evolvable in terms of cross-
species transmission.  
My previous work has demonstrated that one of the primary barriers to host range 
expansion is host cell receptor incompatibilities (Cockrell et al. 2014, Peck et al. 2015b). 
However, experiments in other coronaviruses have shown that receptor differences can be easily 
overcome. For example, studies in murine hepatitis virus (MHV) found the emergence of host 
range variants following persistent infection (Baric et al. 1999). Four amino acid substitutions in 
the MHV spike gene allowed the virus to successfully infect nonpermissive human and hamster 
59 
cells (McRoy and Baric 2008).  Three mutations in a strain of SARS-CoV isolated from a civet 
were required for successful infection and replication in human cells (Sheahan et al. 2008), 
although this was accompanied by a tradeoff in binding affinity to either civet or human ACE2 
(Wu et al. 2012a). Additionally, a single mutation in the spike protein was associated with 
increased mouse ACE2 receptor usage (Roberts et al. 2007). These data suggest that 
coronaviruses can easily adapt to utilize receptor orthologs and engage in cross-species 
transmission. As we improve our understanding of the DPP4 biochemical interface, we will have 
a better grasp on predicting which orthologs MERS-CoV may be most likely to adapt to, and 
which species may be the most likely candidates for MERS-CoV host range expansion.  
The biochemical determinants of MERS-CoV permissivity can inform the potential 
evolution of host range by the virus. The knowledge that other DPP4 orthologs can act as 
backbones to support infection (Cockrell et al. 2014, Raj et al. 2014, van Dormelan et al. 2014) 
suggests that in theory, it is possible for MERS-CoV to expand into currently nonpermissive 
hosts. However, experimental results to date indicate that it may not be easy for the virus to 
adapt to these alternate receptors. First, the presence of glycans as barriers can dramatically 
disrupt the interaction between the MERS-CoV RBD and DPP4 (Peck et al. 2015b). Second, 
changing the interactions on both blades IV and V of nonpermissive DPP4 orthologs, as seen 
with mouse and hamster studies (Cockrell et al. 2014, van Dormelan et al. 2014, van Dormelan 
et al. 2016), is crucial. Both of these observations suggest that multiple mutations in the spike 
protein would be required for a virus to efficiently utilize these orthologous receptors. The 
probability of these mutations occurring simultaneously in the same genome may be unlikely, 
depending on the actual number of changes needed. If MERS-CoV does readily adapt to 
orthologous receptors, another question is what changes are needed to promote increased 
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transmission between species or between individuals within a species. Currently, no transmission 
model exists for coronaviruses, creating a gap in our ability to experimentally evaluate the 
evolution of enhanced transmissibility.  
A powerful tool for evaluating whether MERS-CoV can evolve to utilize a nonpermissive 
host cell receptor is to perform adaptation experiments in vitro. Thus I performed passaging 
experiments of MERS-CoV on wildtype mDPP4 to determine whether MERS-CoV could adapt 
to a glycosylated DPP4 molecule. The benefit of this experiment is that it 1) allows me to 
document the mutations necessary for host range expansion at a receptor level, specifically 
following the adaptation pathway of mutations, and 2) produces a mouse-adapted MERS-CoV 
strain that can be used to study pathogenesis. While the developed mouse models provide a basis 
for beginning these studies, the production of a mouse-adapted MERS-CoV would broaden the 
span of possible research by allowing studies in different genetic backgrounds and without the 
caveats associated with transgenic mouse models (see Chapter 1). Of note is that adaptation of 
MERS-CoV to a glycosylated receptor will likely drive the virus away from high efficiency 
binding to hDPP4, potentially reducing the risk of this virus to human infection.   
3.2 Adaptation of MERS-CoV to glycosylated DPP4 receptors 
 Developing a mouse model that can be used to study MERS-CoV pathogenesis is crucial 
for the development of vaccines and potential therapeutics. The previously produced mouse 
models, however, are not ideal, due to issues of non-specific (Agrawal et al. 2015) or transient 
(Zhao et al. 2014) expression. These issues make the development of a mouse-adapted MERS-
CoV appealing. A virus that can infect wildtype mice not only permits more researchers to 
engage in pathogenesis studies, but also allows for investigating different mouse genetic 
backgrounds. Chapters 1 and 2 reveal that a crucial barrier to MERS-CoV infection is 
61 
glycosylation of the DPP4 receptor. This is evident when the removal of glycosylation allows 
mDPP4 to support MERS-CoV infection (Figure 1.7A) and the addition of glycosylation to 
hDPP4 restricts MERS-CoV infection (Figure 1.6A). Additionally, permissivity of additional 
DPP4 orthologs, primarily fDPP4 and haDPP4, seems to require the removal of glycosylation 
(Figures 2.7A and B), although other unknown determinants also play a role. Unfortunately, 
because the crystal structure of mDPP4 has not been solved, we cannot use computational 
modeling to engineer a virus that is capable of infecting mDPP4. However, we can try adapting 
MERS-CoV around the glycan barrier. 
 Adaptation of MERS-CoV to mDPP4 could reveal insights to the mutational pathways 
that coronaviruses take to gain compatibility with new host species receptors. To date, the 
mutational pathway that MERS-CoV took to expand from bats into humans is unknown. A 
camel intermediate host species is the primary hypothesis (Reusken et al. 2013, Gossner et al. 
2014), but it is uncertain whether specific changes in the spike protein facilitated the infection of 
camels, and then the subsequent infection of humans. Without identification of the MERS-CoV 
progenitor, we are unable to retrace its adaptation trajectory to understand what changes were 
required and whether those changes were stochastic or driven by some selective pressure. 
Furthermore, these adaptation experiments can help reveal whether MERS-CoV is even capable 
of adapting around a glycan barrier. This will have implications for 1) potential mechanisms of 
host evolution to evade viral infection and 2) whether MERS-CoV (or MERS-like coronaviruses) 
can potentially emerge into these nonpermissive species in nature. 
 Previous studies have found that experimental adaptation of an RNA virus to a new host 
can be successful when a host invasion strategy is used (Morley et al. 2015). Briefly, the 
population starts in an environment that is composed of 100% permissive and 0% nonpermissive 
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hosts. The population is then passaged with a decreasing proportion of permissive to 
nonpermissive hosts until the latter makes up 100% of the population. Using this strategy, I 
performed two treatments of permissive-nonpermissive host combinations: the first uses hDPP4-
expressing cells as the permissive host and hDPP4 + gly-expressing cells as the nonpermissive 
host (Figure 3.1); the second uses mDPP4 288, 330-expressing cells as the permissive host and 
mDPP4 288-expressing cells as the nonpermissive host (Figure 3.2). For these experiments, I 
created NIH 3T3 cell lines stably expressing the appropriate DPP4 variant. Using a mouse cell 
line for adaptation experiments better recapitulates the eventual environment the virus will 
encounter and prevents selection for human cell line-adapted mutations. One observation of note, 
however, is that human cell lines seem to more faithfully glycosylate putative sites compared to 
 
Figure 3.1: Host invasion adaptation strategy using hDPP4 as a backbone 
Adaptation experiment design using a host invasion strategy. (A) Wildtype MERS-CoV is 
passaged on a mixture NIH 3T3 cells expressing either hDPP4 or hDPP4 + gly. Over time, the 
proportion of hDPP4 to hDPP4 + gly decreases until the cell population is composed entirely of 
hDPP4 + gly. (B) The hDPP4 + gly sequence uses hDPP4 as a backbone and swaps the NLT 
glycosylation site (black box) of mDPP4 in place of the aligning hDPP4 residues. 
A 
B 
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rodent cell lines (Figure 3.3). HEK 293T cells and Huh7 cells (both human) show intermediate 
MERS-CoV infection levels when hDPP4 + gly or mDPP4 330 are overexpressed (Figure 3.3). 
However, when these DPP4 constructs are overexpressed in mouse cells (NIH 3T3 and DBT) or 
hamster cells (BHK), there is no increase in infection (Figure 3.3). This trend holds true for other 
DPP4 constructs that are glycosylated, whether in the hDPP4 or mDPP4 backbone (data not 
shown). Other studies have found similar variation in levels of glycosylation between different 
cell types and this discrepancy has had an impact on coronavirus species specificity (Wentworth 
and Holmes 2001, Li et al. 2005b). However, more studies are needed to fully understand 
whether the difference seen here in the context of DPP4 truly is variation in the level of 
glycosylation fidelity within these cell lines. However, if this hypothesis proves true, it could 
suggest that glycosylation would not be a proper barrier to infection in hDPP4 (and/or other 
permissive non-glycosylated DPP4 orthologs) in vivo. 
 
 
Figure 3.2: Host invasion adaptation strategy using mDPP4 as a backbone 
Adaptation experiment design using a host invasion strategy. Wildtype MERS-CoV is passaged 
on a mixture NIH 3T3 cells expressing either mDPP4 288, 330 or mDPP4 288. Over time, the 
proportion of mDPP4 288, 330 to mDPP4 288 decreases until the cell population is composed 
entirely of mDPP4 288.  
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Each NIH 3T3 cell line used in the following adaptation experiments stably expresses the 
indicated DPP4 construct. NIH 3T3 cells were transfected with each DPP4 variant and then 
selected with Bleocin (EMD Millipore) in order to isolate those cells that had successfully 
integrated the plasmid into their genomes. Selection was maintained on the cells to prevent 
reversion of the population; however, infection experiments were carried out with fresh media 
(i.e., no Bleocin was present during passaging of the virus). Stable NIH 3T3 cell lines were 
established expressing the following DPP4 constructs: hDPP4, hDPP4 + gly, mDPP4, mDPP4 
288, and mDPP4 288, 330. To test for successful selection of cells with integrated DPP4 genes, I  
 
Figure 3.3: DPP4 panel tested on human, mouse, and hamster cell lines 
Five DPP4 constructs were tested for permissivity using five different cell lines. 945-venus 
construct used as a control for transfection efficiency. Human cell lines include 293T and Huh7; 
mouse cell lines include NIH 3T3 and DBT; hamster cell lines include BHK. hDPP4, hDPP4 + 
gly, mDPP4, mDPP4 330, and mDPP4 288, 330 were overexpressed in each cell line and 
infected with MERS-CoV-RFP. 293T (red) and NIH 3T3 (blue) cell names indicate the two used 
in this dissertation. 
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analyzed three of the cell lines by immunofluorescence (Figure 3.4). Staining for DPP4 shows 
high levels of DPP4 expression on the surface of the cells, recapitulating the expected 
endogenous localization of DPP4. 
After generating these cell lines, I characterized the growth curve for both of the 
permissive (starting) cell lines to be used: hDPP4 and mDPP4 288, 330 (Figure 3.5). T75 flasks 
of each cell type were infected with rMERS-CoV-RFP at an MOI of 0.01. Supernatant samples 
were taken at 0, 6, 12, 18, 24, 48, 72, and 96 hours post-infection and viral titers measured via 
plaque assay. Determining the growth curves informed the selection of an incubation period that 
ensured peak viral titer for both cell lines before passaging. Both stable cell lines reach their peak 
viral titer at 72 hours post-infection (Figure 3.5B). In fact, NIH 3T3 cells expressing hDPP4  
 
 
Figure 3.4: DPP4 construct expression in stably expressing NIH 3T3 cells  
DPP4 and mutant variants are expressed on the surface of cells, visible by immunofluorescence 
(IFA). NIH 3T3 cells were transfected with the given DPP4 variant and selected for stable 
expression using Bleocin. After obtaining a population of Bleocin-resistant cells, cell lines were 
seeded, fixed, and probed with primary goat-anti-DPP4 polyclonal antibody (R&D Systems) at 
1:50 and secondary donkey-anti-goat Alexa Fluor 488 (Life Technologies) at 1:500. Cells were 
imaged at 40X for DAPI (30 ms exposure) and DPP4 (160 ms exposure). The hDPP4 + gly 
variant has the hDPP4 backbone sequence with the mDPP4 glycosylation site swapped in (see 
Figure 3.1B) 
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reach viral titers that are equivalent to when MERS-CoV is grown in Veros (monkey cells; 
permissive) (Figure 3.5B). Due to these results, virus populations were transferred at 72 hours 
for each passage. 
For the start of the adaptation experiments, only NIH 3T3 cells stably expressing hDPP4 
or mDPP4 288, 330 were seeded in separate T75 flasks and infected with rMERS-CoV-RFP at 
an MOI of 1 (Passage 1). At 72 hours post-infection, the supernatant was harvested and 2 mL 
 
 
Figure 3.5: Growth curve of permissive NIH 3T3 stably-expressing cell lines 
NIH 3T3 cell lines stably expressing hDPP4 and mDPP4 288, 330 were generated and rMERS-
CoV-RFP infection (MOI 0.01) tracked over time. (A) Infections were imaged at 24, 48, 72, and 
96 hpi. Veros are a positive control for infection and wildtype NIH 3T3s are a negative control. 
(B) Viral titers (PFU/mL) were measured at various time points for each cell type. Peak titers are 
reached by both stable cell lines by 72 hpi. 
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Figure 3.6: Host invasion adaptation of MERS-CoV to hDPP4 + gly 
rMERS-CoV-RFP was passaged on NIH 3T3 cells stably expressing hDPP4 or hDPP4 + gly. 
Passage 1 included 100% hDPP4 cells and decreased by 10% hDPP4 each passage. At passage 
10, the percentage of permissive cells was increased to 40% and decreased by 10% every other 
passage (see Figure 3.8). Each passage was at an MOI of 1, with a ~72 hour incubation period. 
Images were taken at ~72 hpi before the next round of infection. 
 
Figure 3.7: Host invasion adaptation of MERS-CoV to mDPP4 288 
rMERS-CoV-RFP was passaged on NIH 3T3 cells stably expressing mDPP4 288, 330 or mDPP4 
288. Passage 1 included 100% mDPP4 288, 330 cells and decreased by 10% each passage. At 
passage 10, the percentage of permissive cells was increased back to 100% and decreased by 
10% every other passage (see Figure 3.8). Each passage was at an MOI of 1, with a ~72 hour 
incubation period. Images were taken at ~72 hpi before the next round of infection. 
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transferred to a fresh T75 flask of cells with 90% hDPP4 and 10% hDPP4 + gly, or 90% mDPP4 
288, 330 and 10% mDPP4 288 (Passage 2) at an MOI of ~1. At each passage, the cells were 
visualized (Figures 3.5 and 3.6) and viral titer measured via plaque assay (Figure 3.8). Based on 
the earlier passages, it appeared as though changing the percent permissive host by 10% was too 
rapid of a change for the viral population to have the opportunity to allow beneficial mutations to 
increase in frequency (Figures 3.5 and 3.6). In the work done by Morley et al. (2015), the rate of 
change in the population composition did play an important role in the adaptation and endpoint 
fitness of the viral population. Adjusting my approach, at passage 10, I increased the permissive 
 
 
Figure 3.8: Virus titer and percent permissive host cells for host invasion adaptation experiments 
Virus titer (left y-axis, PFU/mL) against passage number for both host invasion treatments. 
hDPP4 treatment includes hDPP4 stably expressing NIH 3T3 cells as the permissive host and 
hDPP4 + gly as the nonpermissive host (purple). mDPP4 288, 330 treatment includes mDPP4 
288, 330 stably expressing cells as the permissive host and mDPP4 288 as the nonpermissive 
host (blue). Cell composition is represented by percent permissive (right y-axis) which indicates 
the percent of the culture that was composed of permissive host cells (hDPP4, solid gray line; 
mDPP4 288, 330, dashed gray line). 
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host percentage to 40% for the hDPP4 treatment and 100% for the mDPP4 288, 330 treatment 
(Figure 3.8, gray lines). Subsequent passages decreased the percent  permissive host by 10% 
every other passage (instead of every passage). The titers of both populations seem to increase 
over time, albeit with a consistent decrease at the first drop in permissive host percentage. 
However, the detection of red fluorescence from imaging seems to decrease steadily over time 
(Figures 3.5 and 3.6), providing contradictory results. 
One possible explanation is that the rMERS-CoV-RFP virus has kicked out the RFP tag 
over time. Because the RFP is not crucial for replication, a virus that has a deletion in this region 
would replicate more quickly and have a greater fitness than other viral variants. To test whether 
the RFP tag was still present in the adapting populations, and to evaluate whether any adaptation 
has occurred, I tested passage 25 virus populations from both the hDPP4 and mDPP4 288, 330  
 
Figure 3.9: Infection panel of passage 25 virus from two adaptation experiment treatments 
Three virus populations were tested for successful infection on NIH 3T3 cell lines stably 
expressing five different DPP4 constructs: hDPP4, hDPP4 + gly, mDPP4, mDPP4 288, and 
mDPP4 288, 330. Wildtype rMERS-CoV-RFP (top row); passage 25 from the hDPP4 treatment 
(middle row, see Figure 3.6); and passage 25 from the mDPP4 288, 330 treatment (bottow row, 
see Figure 3.7). Cells were infected at an MOI of 1 and imaged 48 hpi. 
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treatments on NIH 3T3 cells stably expressing: hDPP4, hDPP4 + gly, mDPP4, mDPP4 288, and 
mDPP4 288, 330. Wildtype rMERS-CoV-RFP virus was used as a positive control. Each cell 
type was infected with the three virus populations (hDPP4 P25; mDPP4 288, 330 P25; and 
wildtype rMERS-CoV-RFP) at an MOI of 1, and the cells imaged ~48 hpi (Figure 3.9). Results 
show that fluorescence can be seen when both virus populations are tested against mDPP4 288, 
330. However, infection is only visible on the hDPP4 construct when the hDPP4 treatment 
population is tested (Figure 3.9). This indicates 1) that the populations did not lose RFP 
expression and 2) that the mDPP4 288, 330 treatment population may be evolving to better 
utilize the mDPP4 backbone and become less efficient at utilizing hDPP4. Additional analyses 
are needed to determine whether the fluorescence visualized in Figure 3.9 is truly indicative of 
each population’s ability to utilize the panel of receptors. Sequencing of both populations at 
passage 25 to evaluate any mutations in the spike protein is currently in progress. 
 The inability of MERS-CoV to easily adapt around a blade V glycan suggests that 
generating a mouse-adapted MERS-CoV by passaging may be biologically intractable. Even 
when the virus is, presumably, well-adapted to the backbone molecule of hDPP4, the population 
is unable to restructure its RBD in order to infect utilizing the hDPP4 + gly receptor variant 
(Figures 3.6 and 3.8). Using mDPP4 as a backbone also did not result in successful adaptation 
(Figures 3.7 and 3.8). These results support the hypothesis that multiple mutations are required in 
order to overcome the barrier of glycosylation. With multiple mutations needed, the probability 
of sampling a successful variant decreases dramatically. Even within 25 passages, both 
populations were unable to sample enough sequence space to encounter such a variant, if one is 
biologically possible.  
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There are two evident solutions to the dilemma of multiple mutations being required to 
produce a mouse-adapted MERS-CoV. The first is to crystallize the mDPP4 molecule and 
computationally predict the RBD remodeling that would need to occur to bind around 
glycosylation. The identified mutations could then be reverse engineered into the MERS-CoV 
genome to produce a variant capable of infecting wildtype mice. The second is to enhance the 
genetic variation available to the population; this can be done by chemical mutagenesis or by 
production of a mutator allele. Due to the evolutionary implications of the latter, I propose to 
investigate whether a mutator allele can facilitate host range expansion by increasing the genetic 
variation of a population and producing sequence variants that could successfully infect a new 
species. 
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4. FUTURE DIRECTIONS 
4.1 Development of a MERS-CoV mutator 
The high mutation rates of RNA viruses give them the ability to evolve rapidly, 
particularly when combined with their large population sizes and short generation times. 
However, most mutations are lethal or deleterious (Sanjuan et al. 2004, Stern et al. 2014). The 
large number of deleterious mutations can cause high mutation rates to be disadvantageous by 
pushing the population closer to the extinction threshold – the mutation rate becomes so high that 
the deleterious mutation load causes the mean fitness of the population to decrease to such an 
extent that the population goes extinct (Bull et al. 2007). RNA viruses exist close to this 
threshold, as shown through lethal mutagenesis experiments in many different RNA viruses 
(FMDV, (Sierra et al. 2000); poliovirus, (Crotty et al. 2001)). In fact, it has been suggested that 
most RNA viruses replicate at an optimum mutation rate that maximizes fitness, virulence 
(Korboukh et al. 2014), and evolvability (Sanjuan 2012) without crossing the extinction 
threshold. 
 Despite the proximity of RNA viruses to the extinction threshold, mutator alleles have the 
potential to play a role in promoting host range expansion. A mutator allele increases the 
inherent mutation rate of a virus and thus enhances the genetic variation of the population; this 
variation may harbor mutations that are beneficial or required for expansion into a new host. If 
the benefit of a mutation that allows a virus to jump into a new host outweighs the cost of an 
increased deleterious mutation load compared to wildtype, the mutator allele has the potential to 
increase in frequency in the population. This increase comes in the form of hitchhiking – the 
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mutator allele hitchhikes along with the beneficial mutation that it produced. Note that 
hitchhiking is dependent on asexual reproduction (i.e., no recombination) so the mutator remains 
linked to the beneficial mutation it produced. This works best when a single beneficial mutation 
can confer an advantage; in more complex systems where adaptation requires multiple beneficial 
sites, recombination plays an important role in bringing these mutations onto the same 
background. The hitchhiking of mutator alleles has been well documented in other organisms, 
such as bacteria (Sniegowski et al. 2000, Shaver et al. 2002), but has yet to be experimentally 
demonstrated in a viral system. Still, theory supports that mutators will be favored by natural 
selection in the face of novel environments (Taddei et al. 1997, Tanaka et al. 2003), such as that 
presented by a new host species. 
Mutator phenotypes have been isolated from natural populations of HIV-1 (Gutierrez-
Rivas and Menendez-Arias 2001) and influenza A virus (Suarez et al. 1992). Additionally, 
targeted mutations have resulted in mutator strains for poliovirus (Liu et al. 2013, Korboukh et 
al. 2014), coxsackievirus B3 (Gnadig et al. 2012), chikungunya virus (Rozen-Gagnon et al. 
2014), foot and mouth disease virus (Xie et al. 2014) and coronaviruses (Eckerle et al. 2007, 
Eckerle et al. 2010, Graham et al. 2012). However, coronaviruses are the only RNA viruses that 
have evolved a replication proofreading mechanism independent of the RNA polymerase. The 
nsp14 gene, known as ExoN, has 3’-to-5’ exoribonuclease activity that is similar to the 
proofreading activity of DNA polymerases (Minskaia et al. 2006). This proofreading capability 
has several implications. First, it likely allowed coronaviruses to expand their genome size past 
that of other viruses (Gorbalenya et al. 2006, Lauber et al. 2012). Second, it allows the 
production of mutator alleles that are outside of the polymerase. When nsp14 is mutated in either 
MHV or SARS-CoV, the virus suffers from a 16 to 20-fold increase in mutation rate (Eckerle et 
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al. 2007, Eckerle et al. 2010), otherwise known as a mutator phenotype. Experiments with the 
SARS-CoV mutator show that in direct competition with wildtype, the mutators quickly die out 
when no selection is present (Graham et al. 2012). This suggests a cost to the mutator allele, 
whether directly through the mutation itself or indirectly through the accumulation of deleterious 
mutations. However, the fact that viable mutators are likely to easily arise through mutations in 
nsp14 suggests that they may be influential in shaping the evolution of coronaviruses when a 
selective pressure is present, such as that of a new host or immune system. One caveat, however, 
is that if the in vivo MOI is high, coinfection of cells can result in recombination of the mutator 
with wildtype genomes, thus uncoupling the mutator allele from the beneficial mutations that it 
produced. This is a particular concern for coronaviruses which have been shown to have up to 
25% recombination rates in vitro (Baric et al. 1990). Improved in vivo recombination and 
coinfection rate estimates will help inform the potential for mutators to succeed in wildtype 
populations. 
Mutators have been implicated as potential factors in previous host range expansion 
events. For example, phylogenetic data suggest that an avian influenza virus (H1N1) jumped into 
pigs and then into humans about 100 years ago (Webster et al. 1992), with a mutator allele as the 
primary hypothesis for how the virus could rapidly cross two species barriers (Ludwig et al. 
1995). When the H1N1 avian influenza jumped into European swine again in 1979, a mutator 
allele was thought to be responsible. However, even though evolution rates were higher in the 
new influenza strain compared to the ancestral strain, its mutation rate was not (Stech et al. 
1999). While the role of a mutator in this host range expansion event is highly speculative and 
controversial, mutators may still play a role in influenza evolution since clinical isolates have 
been readily identified with mutation rates 3-4 times greater than in ancestral strain (Suarez et al. 
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1992), suggesting that natural populations could contain high frequencies of mutators at any 
given time. Additionally, mutator strains of norovirus (NoV) have been suggested to play an 
important role in the recent NoV pandemics. Using in vitro RdRp assays, the mutation rates of 
various genogroup II genotype 4 (GII.4) strains in addition to less common GII.b/GII.3, GII.3, 
and GII.7 strains (Bull et al. 2010) were measured. The mutation rates of the predominant GII.4 
strains were 5 to 36-fold higher than the less frequently detected lineages. This evidence suggests 
that increased inherent mutation rate can enhance the epidemiological fitness of circulating virus 
strains. 
Mutators have not yet been implicated for host range expansion in coronaviruses, but this 
could simply be due to a lack of discovery. While the mutation rate of the original SARS-CoV 
isolate has been measured (9 x 10-7 substitutions per nucleotide per replication cycle, (Eckerle et 
al. 2007)), the mutation rates of closely related bat coronaviruses have not. Furthermore, the 
mutation rate of MERS-CoV has not yet been experimentally determined, although the evolution 
rate has been estimated at 1.12 x 10-3 substitutions per site per year (Cotten et al. 2014) which is 
comparable to the SARS-CoV estimate of 2.82 x 10-3 (Lau et al. 2010). It would be interesting to 
compare the MERS-CoV mutation rate with those of BtCoV-HKU4 and BtCoV-HKU5. If a 
mutator allele was responsible for producing the variation necessary for MERS-CoV to emerge 
in humans, we would expect it to have a higher inherent mutation rate than those of closely 
related lineages circulating in bats. Furthermore, mutators may play an important role in 
coronavirus vaccine development. The SARS-CoV mutator has been shown to be attenuated in 
vivo with no reversion to virulence following passaging or persistent infection (Graham et al. 
2012), providing a promising starting candidate for further development. Additionally, while 
SARS-CoV is resistant to ribavirin (Chiou et al. 2005, Barnard et al. 2006), the mutator strain is 
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not (Smith et al. 2013). This suggests that a possible therapeutic strategy could be to combine 
mutagens with inhibitors of nsp14 activity. Further studies can help advance the use of mutators 
in the development of vaccines and therapeutics. 
Whereas mutators have been readily engineered for murine hepatitis virus (MHV) and 
SARS-CoV (Eckerle et al., 2007, Eckerle et al. 2010), a successful mutator has not yet been 
produced for MERS-CoV. Generating a mutator for MERS-CoV to add to the panel of 
coronavirus mutators is beneficial for many reasons. First, it can increase our understanding of 
the potential for MERS-CoV to expand its host range to other species. While utilizing chemical 
mutagenesis would allow for similar tests of the impact of enhanced genetic variation, 
developing a mutator is crucial for directly testing whether mutators play a significant role in 
promoting host range expansion events. This outcome is directly applicable to naturally 
circulating coronavirus populations. Second, a MERS-CoV mutator can help us characterize the 
range of potential antibody escape mutants, having high relevance to pathogenesis and the future 
development of therapeutics. Third, the SARS-CoV mutator has been explored as a potential 
player in vaccine design due to its increased attenuation in vivo (Graham et al. 2012), implying 
that a MERS-CoV mutator may serve a similar application. Overall, mutator alleles have a wide 
range of applications, including being used to explore questions of polymerase fidelity 
(poliovirus, Pfeiffer and Kirkegaard 2003), antibody escape (Bayliss et al. 2008), drug resistance 
(HIV, Mansky and Bernard 2000; HSV-2, Nishiyama et al. 1985), attenuation of pathogenesis 
(coronavirus, Graham et al. 2012; coxsackievirus B3, Gnädig et al. 2012), and lethal 
mutagenesis (FMDV, Sierra et al. 2000). 
My strategy for identifying a mutator allele makes use of a thorough understanding of 
mutator dynamics in DNA-based organisms, achieved through the combination of population 
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genetics and evolution experiments (Sniegowski et al.1997, Chao and Cox 1983). These studies 
show that mutators are favored under three primary conditions. First, the population must be 
adapting. The presence of a selective pressure ensures that beneficial mutations are possible, 
resulting in the mutator strain having an increased probability to produce the beneficial mutation 
before the wildtype strain. Second, the population must reproduce asexually. This ensures that 
the mutator will increase in frequency by hitchhiking along with the beneficial mutation that it 
produced. Third, the cost of the mutator allele must not be too high, or rather, the benefit of the 
beneficial mutation must be greater than both the direct cost of the mutator allele (the mutation 
itself) and the indirect cost of an accumulation of deleterious mutations elsewhere in the genome.  
Previous attempts at generating a MERS-CoV mutator have been unsuccessful; namely, 
introducing the same mutations into MERS-CoV that produce a mutator in SARS-CoV and 
 
Figure 4.1: Sequence and structural alignment of SARS-CoV and MERS-CoV nsp14 
(A) MERS-CoV and SARS-CoV nsp14 sequence alignments with the second and third D residue 
of the DEDD motif highlighted (black boxes). Red lines indicate which residues were chosen in 
MERS-CoV for generating a codon library. (B) Structural alignment of SARS-CoV (red; PDB 
code 5C8U) and MERS-CoV (blue; threaded using I-TASSER (Zhang 208)) nsp14. Amino acids 
representing the DEDD motif are shown in orange (SARS-CoV) and light blue (MERS-CoV), 
with the residues adjacent to the DEDD sites visible in red (SARS-CoV) and blue (MERS-CoV). 
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MHV (Eckerle et al. 2007, Eckerle et al. 2010) are inviable in the context of MERS-CoV (data 
not shown). These mutators were achieved by mutating one to two of the DEDD motif residues 
to alanines; additional attempts to change these four residues to other amino acid identities also 
failed (personal correspondence with Mark Denison). Thus, in order to identify a MERS-CoV 
mutator, specifically one with a low-fitness cost, I generated a pool of potential mutators by 
creating a library of nsp14 mutants. However, instead of making mutations within the DEDD 
motif residues, I created a codon library (i.e. all permutations of each codon) at residues adjacent 
to the DEDD active site residues (Figure 3.10A). Assuming that the active sites in the context of 
MERS-CoV are too sensitive to tolerate mutations, changing the amino acids adjacent to the 
active site residues may alter the structure enough to decrease fidelity without resulting in an 
inviable variant.  
Residues for my codon library were chosen based on a sequence and structural 
comparison with SARS-CoV nsp14 (Figure 4.1). Two residues (six nucleotides) were chosen 
directly adjacent to a DEDD active site residue; this number of nucleotides is based on the 
number of variants that would be experimentally tractable. With six positions and four different 
nucleotides, there are over 4,000 possible sequence combinations. This reaches the threshold of 
the number of viruses that will be successfully transcribed and electroporated into cells to 
produce infectious virions during the reverse genetics process. Although redundant codons will 
cause some amino acid combinations to be more represented than others, including more 
residues in our library would only enhance this bias.  
 Another consideration for my selection criteria is that nsp14 is present across two of the 
seven plasmids that are used in the MERS-CoV infectious clone system (see Scobey et al. 2013). 
This has the benefit of generating codon libraries on two plasmids that can be used to produce 
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variants individually or in combination. Selecting active sites that are represented on both 
plasmids increases my ability to generate variant combinations and potentially identify a viable 
mutator strain. For example, each plasmid will have 202 amino acid combinations; when these 
two plasmids are combined, the number of variants increases to 204 (or 160,000). One note is 
that the nature of a codon library prevents me from being able to exclude wildtype sequences 
from the virus pools. Even if the exact wildtype sequence was eliminated (e.g., by some 
fortuitous restriction sites), alternate codons that result in the same amino acid sequence would 
also need to be eliminated. Thus my downstream experiments keep in mind that most 
populations will have some (or many) wildtype sequences that will outcompete mutator variants 
in environments with no selection (Graham et al. 2012).  
  I used sequence and structural information to choose the residues to compose my codon 
library. I noted both the conservation of amino acid identities at adjacent DEDD residues to 
SARS-CoV (Figure 4.1A) and the structure of those amino acids around the active sites (Figure 
4.1B). Even though the MERS-CoV nsp14 structure used here is a predicted molecule threaded 
using I-TASSER (Zhang 2008), it can still provide useful visual information. After combining 
these analyses, I chose one set of two residues adjacent to the D2 active site (the second D in the 
DEDD motif) that were nonconserved with SARS-CoV (Figure 4.1A). The second set I chose 
was adjacent to the D3 active site and partially conserved with SARS-CoV (Figure 4.1A). 
Examining the structure of these amino acids shows extreme differences adjacent to D2, and 
subtle differences adjacent to D3 (Figure 4.1B). Creating libraries from both of these sequence 
and structural phenotypes will increase the probability of identifying a viable mutator variant, if 
one is biologically possible. 
80 
 Codon libraries were ordered from Biobasic and amplified for virus production. Briefly, 
the infectious clone system utilizes seven plasmids that contain the entire genome (Scobey et al. 
2013). Unique restriction sites (BglI) are located on both the 5’ and 3’ end of the genome 
fragment within each plasmid. Genome fragments are digested and purified before ligation of the 
fragments occurs to form a complete cDNA copy of the genome. Note that the ligation reaction 
and all subsequent virus production steps are carried out in a BSL3 facility. Using the complete 
cDNA copy of the genome as a template, a transcription reaction transcribes the genome into 
RNA. This full-length RNA is then electroporated into Vero cells. Because coronaviruses are 
positive-sense ssRNA viruses, they do not require extra machinery to be included along with the 
genome copies; once inside, the genome is translated into protein and the virus produces all of 
the components needed to complete its replication cycle. After ~72 hours, viral progeny are 
harvested from the culture supernatant and these virions represent fully infectious particles 
originating from the electroporated sequences. As noted above, however, this process is not 
highly efficient; the yield of each step decreases such that the final harvested virus is a fraction 
of the original input. 
 
Figure 4.2: Pooled and plaque isolated rMERS-CoV-RFP D2 mutator virus 
rMERS-CoV-RFP D2 mutator virus populations. (A) rMERS-CoV-RFP mutator viruses are 
electroporated into Vero cells and grown as a pooled population. Cells are imaged ~72 hpi. (B) 
rMERS-CoV-RFP mutator viruses are grown on an agarose plate, allowing individual plaques to 
be isolated. Plaques are grown in a 96-well plate of Vero cells and imaged at ~72 hpi. Viruses 
shown here are made from the plasmid with the codon library adjacent to D2 (second D of the 
DEDD motif, see Figure 4.1). 
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Based on pilot experiments for mutator virus production, it seems as though the majority 
of mutant variants (not necessarily mutator phenotypes) are inviable. Pools of viruses were 
harvested from the initial electroporation products; imaging showed high levels of infection from 
the pooled samples (Figure 4.2A). However, sequencing of this pool suggests that the majority of 
sequences present are, in fact, wildtype (data not shown). Additionally, instead of electroporating 
and growing the potential mutator variants as a pool, I also grew them on an agarose plate. This 
removes competition and allows each virus to grow as an isolated plaque. Each plaque was then 
harvested and grown in a separate well of a 96-well plate. Imaging of each individual well shows 
high levels of variation in infection levels (Figure 4.2B). This suggests that even if I am not 
successful in the production of a fidelity variant (e.g., increase or decrease in mutation rate), 
there is variation in overall fitness. 
Plaque-isolated viruses were also heavily biased toward the wildtype sequence. In the 
first replicate, 84 plaques were isolated, grown, and sequenced. Out of these, 39 were wildtype 
(46.4%), 42 had indistinguishable sequences (50%), and 3 were a clear non-wildtype sequence 
(3.6%). This is discouraging because it suggests that 1) wildtype is outcompeting variants 
rapidly, perhaps in a manner independent from growth rate and burst size in the context of a 
pooled population; or 2) most mutations in the nsp14 gene are inviable. The expected wildtype 
(sequence) frequency in our library is 0.20% for the D2 mutator ((21 ×  41) 46 = 0.002)⁄ , and 
0.30% for the D3 mutator ((61 ×  21) 46 = 0.003⁄ ). However, this expected frequency assumes 
that each codon is represented equally when the cDNA is transcribed into RNA. Additionally, 
while the above values represent the expected wildtype sequence, the possibility of a mutation 
that still results in a wildtype phenotype cannot be excluded. Thus, more replicates and 
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sequencing are needed to understand the wildtype bias seen above and whether any mutator 
strains are present in the viruses generated. 
Once I have generated a pool of viruses that I am confident has a proportion of non-
wildtype sequence variants, the aforementioned population biology approach can help identify a 
low-fitness cost mutator. Pooled virus will undergo passaging (and hence, competition) under 
conditions where the population will be either adapting (with monoclonal antibody selection) 
(Figure 4.3) or not adapting (without monoclonal antibody selection). Recall that a mutator is 
expected to increase in frequency when: 1) the population is adapting; 2) the population is 
asexual; and 3) the cost of the mutator is not too high. The novel selective pressure of 
monoclonal antibodies meets the first condition of an adapting population. Several monoclonal 
antibodies have been identified for MERS-CoV (Agnihothram et al. 2014). These antibodies fall  
 
Figure 4.3: Schematic for passaging rMERS-CoV-RFP pooled variants under selection to 
identify a mutator allele 
A codon library of variants (colored virus diagrams) is passaged in the presence of sequential 
monoclonal antibodies against MERS-CoV (blue and gray antibody diagrams). At each passage, 
the population is submitted for deep-sequencing. Mutator viruses are expected to increase in 
frequency over time and wildtype (sequence and phenotype) viruses are expected to decrease in 
frequency. 
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into three groups that neutralize different epitopes on the MERS-CoV spike protein, without 
cross-neutralization between groups. Additionally, escape mutants have been readily identified 
for all except one of these antibodies (Agnihothram et al. 2014). This confirms that escape 
mutants are capable of being produced, and also improves my ability to determine how much 
time and genetic variation would be required for a mutator to produce an escape mutant before 
the wildtype population. To meet the second condition of an asexually reproducing population, 
the MOI is kept very low (e.g., 0.001) to prevent two virions from infecting the same cell where 
their genomes could recombine. For the third condition, cost of the mutator cannot be controlled, 
but the use of a codon library improves the chance that there is a low-fitness cost mutator variant 
in the population. 
I expect the wildtype virus to reach the highest frequency in an environment without 
selection. If a variant reaches a similar or greater frequency than wildtype, it is unlikely to be a 
mutator; mutators will produce more deleterious mutations than wildtype and will be unable to 
gain an advantage since beneficial mutations are not present in an environment without selection. 
I expect mutator viruses to reach the highest frequency in an environment with selection. 
Mutators will be more likely to produce escape variants compared to wildtype, which will be 
favored under the selective pressure of neutralizing monoclonal antibodies. Among mutators, 
strains with the lower fitness costs will be favored above other mutators and will reach higher 
frequencies. Here, deep sequencing allows me to not only identify a set of potential mutator 
alleles through comparison of mutant frequencies in the two population treatments, but also 
attribute fitness costs to those alleles. After potential mutators have been identified by deep 
sequencing, the actual mutation rate can be measured by passaging a population of each potential 
mutator - generated by reverse genetics using the infectious clone system - and sequencing at 
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regular intervals to count the number of mutations that occur for each approximate replication 
cycle (see Eckerle et al. 2010). 
 The importance of understanding mutators and the potential role they play in promoting 
host range expansion and viral emergence has not gone unnoticed (Mansky and Cunningham 
2000, Smith et al. 2014). However, the tractability of testing these in an experimental setting has 
thus far been absent. Here, I present an approach for characterizing host range expansion and the 
role of mutators in an RNA virus system. First, MERS-CoV has a clearly defined spike-receptor 
relationship with various DPP4 orthologs (see Chapters 1 and 2), resulting in a panel of 
permissive and nonpermissive receptors that can be used to understand the mechanisms of host 
range expansion. This is given further power by the mutant mDPP4 molecules generated in 
Chapter 1, which will allow me to fine-tune the characterization of permissivity. Second, the 
convenience of the coronavirus infectious clone system allows us to test hypotheses by directly 
mutating or constructing specific viral variants. Third, the presence of an RdRp-independent 
proofreading mechanism allows us to generate viable mutator strains that can be used to explore 
various aspects of mutator dynamics in an RNA virus population.  Based on our previous 
knowledge of the relationship between mutation rate and evolution rate (Figure 0.1), the 
presence of proofreading in coronaviruses presents an interesting case study. It is fathomable that 
a population would fix a mutator allele in a selective environment, thus causing the population to 
overcome a pressure such as a new host species, and then revert back to the wildtype mutation 
rate in order to reduce the number of deleterious mutations accumulating in the population. 
Whether this is a viable scenario in a wildtype population will be determined by further 
experiments and surveillance research. 
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The coronavirus system is significant because it allows for increases of as much as 20-
fold in the genome-wide mutation rate (Eckerle et al. 2010), compared to the 3 to 4-fold increase 
seen for influenza (Suarez et al. 1992). Utilizing these innovative tools, we can expand future 
experiments to examine 1) the dynamics of species-specific restriction factors by transfecting 
DPP4s into their native host cell types; 2) the prevalence and possible strategies of compensatory 
and/or revertants after a mutator has reached fixation in the population and how this can impact 
host range expansion events. Whereas developing a mutator MERS-CoV strain would permit the 
use of an extensive panel of receptor variants (see Chapters 1 and 2), the mutator strains already 
identified for SARS-CoV and MHV can be used to study these questions if additional receptor 
resources were developed. 
4.2 Potential evolutionary mechanisms for coronavirus host range expansion (modified 
from Peck et al. 2015c). 
Understanding the evolutionary mechanisms facilitating viral host range expansion is 
crucial for prevention of, and preparation for, new emerging pathogens. Unfortunately, the forces 
that drive host range expansion events are still relatively unknown. Even for well-studied viruses 
such as influenza viruses, SARS-CoV, and MERS-CoV, the path of emergence and the selective 
pressures preceding emergence are often not clear. Here I discuss two potential evolutionary 
mechanisms, in addition to mutators, that may influence coronavirus host range expansion: 
recombination and mutational robustness (i.e. the ability to remain phenotypically constant or 
functional in the face of genetic perturbations). These topics can be explored in future studies to 
determine their potential impact on the emergence of MERS-CoV. 
Recombination can act to create new viral variants and is a common event in the adaptive 
evolution of RNA viruses (Worobey and Holmes 1999). The ability to generate new genetic 
variants allows viral populations to explore the adaptive landscape at a faster rate than permitted 
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by mutation alone (Shackelton et al. 2005). Recombination has been implicated as a major 
evolutionary force for HIV-1 (Robertson et al. 1995), and has been suggested to contribute to 
host range expansion for many viruses, such as influenza A virus (Scholtissek et al. 1978), 
nuclear polyhedrosis virus (Maeda et al. 1993), and cauliflower mosaic virus (Schoelz and 
Wintermantel 1993). Coronaviruses can have in vitro recombination rates approaching 25 
percent in progeny after a single round of coinfection at high multiplicity of infection (MOI) 
(Baric et al. 1990), likely due to the ability of the RdRp to switch templates during replication 
(Holmes 2003). In fact, recombination has been implicated in the sharing of homologous genes 
by distantly related members of the Coronaviridae family (Worobey and Holmes 1999). 
Phylogenetic analyses have revealed that hCoV-NL63 may have undergone many recombination 
events, including two sites of recombination in the S gene and potential recombination between 
hCoV-NL63 and porcine enteric disease virus (PEDV) in the M gene (Pyrc et al 2006). 
Additionally, evidence suggests that natural avian infectious bronchitis virus (IBV) isolates 
recombined with a vaccine strain (Holland 52), specifically in the nucleocapsid (N) gene (Jia et 
al. 1995). Not only has recombination been detected between coronaviruses, but traces of gene 
acquisition from highly distinct viruses have been detected, such as the transfer of influenza C-
like hemagglutinin-esterase to coronaviruses in the 2a subgroup (Zeng et al. 2008). The potential 
for inter- and intraspecies recombination among coronaviruses gives them the ability to create a 
greater panel of novel and potentially pathogenic genomes.  
The role of recombination in the SARS-CoV emergence is controversial. Initially, it was 
hypothesized that SARS-CoV was a product of recombination between two circulating bat 
coronaviruses, producing a hybrid virus capable of jumping into other species (Rest and Mindell 
2003, Li et al. 2006). Studies suggest that the SARS-CoV M and N genes shared a common 
87 
ancestor with the lineage that eventually became the avian infectious bronchitis coronaviruses 
(Marra et al. 2003, Stavrinides and Guttman 2004). By contrast, the PP1ab polyprotein is most 
similar to murine-bovine coronaviruses, while the S gene is most similar to both the avian and 
group 1 (feline, canine, and porcine) coronaviruses (Stavrinides and Guttman 2004). The 
apparent homology of SARS-CoV with very different clades suggests that extensive 
recombination has occurred in its evolutionary history. However, others argue that SARS-CoV is 
distinct and not a product of a recombination at all (Holmes 2003, Demogines et al. 2012), with a 
false signal for recombination detected due to a diversity in evolution rates between the 
coronavirus lineages (Holmes and Rambaut 2004). Still, recombination occurs frequently in 
natural populations, with recent sequence analyses of SARS-like coronaviruses in horseshoe bats 
in China detecting high levels of recombination between coronavirus strains and even between 
strains from varying geographical locations (Lau et al. 2010). Whereas preliminary phylogenetic 
analyses suggest that MERS-CoV has undergone numerous recombination events in its 
evolutionary history (Dudas and Rambaut 2016), the exact role recombination may have played 
in the emergence of MERS-CoV should be investigated in more detail. Further sampling of bat 
coronaviruses will help to determine the contribution of this evolutionary mechanism.  
Robustness, on the other hand, is the ability of a phenotype to remain constant or 
functional in the face of perturbation, whether environmental or genetic (i.e. mutations). 
Mutational robustness enables a population to explore more sequence space (i.e. sample more 
mutations) without losing viability, thus potentially yielding novel functions or lifecycle 
strategies. In terms of host range expansion, these novel functions could include changes within 
the spike protein that allow the virus to utilize new receptor molecules or evade a new host’s 
immune defenses. While experimentally measuring robustness in virus populations can be 
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complex, competition experiments in vesicular stomatitis virus (VSV) have shown that a more 
mutationally robust virus lineage can have an advantage over a faster-replicating lineage when 
the mutation rate is increased via a mutagen (Sanjuan et al. 2007). This work, combined with 
theoretical studies, suggests that natural selection can favor mutational robustness in viral 
populations (Wilke et al. 2001) and even facilitate adaptation to a novel host under certain 
conditions (Stern et al. 2014).  
Mutational robustness has been suggested to play a role in influenza A virus evolution. 
H3N2 isolates were found to accumulate genetic variation by moving through neutral networks 
(i.e. mutationally-connected genotypes that produce the same phenotype). These periods of 
phenotypic constancy were then disrupted by a sudden phenotypic change in the virus antigenic 
structure. The exploration of sequence space facilitated by a high mutational robustness allowed 
these changes to accumulate and result in epochal shifts that are well matched by 
epidemiological models (Koelle et al. 2006, Lauring et al. 2013). While the H3N2 study found a 
role for robustness in immune evasion specifically, the same process can apply to host range 
expansion. A virus population that could explore a neutral network within the context of the 
spike protein could potentially accumulate changes that increase the likelihood of producing a 
host range mutant. This process could be particularly applicable to MERS-CoV which may 
require multiple mutations to expand its host range to currently nonpermissive species, as 
previously discussed. 
Mutational robustness among RNA viruses varies both among distantly related families 
(Elena et al. 2006) and among closely related strains (Sanjuan et al. 2007). Mutational 
robustness has not been measured in coronaviruses, however the higher resistance of SARS-CoV 
to the mutagen ribavirin (Barnard et al. 2006) compared to that of MERS-CoV (Falzarano et al. 
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2013) suggests a difference in mutational robustness between these viruses (Graci et al. 2012, 
Lauring et al. 2013). Even if coronaviruses are not robust to mutations during the infection of a 
host cell by a single virus, coinfection of host cells by two or more viruses can buffer individuals 
from deleterious mutations. During peak infection (i.e. high viral load), coinfection can occur 
frequently which enables complementation. When multiple genomes contribute to the same 
protein pool, mutant genomes can persist because their more fit coinfection partners compensate 
for their deleterious mutations at the protein level. Experimental evidence has shown that 
complementation results in increased mutational robustness in the RNA bacteriophage Φ6 
(Montville et al. 2005, Joseph et al. 2014) and the maintenance of lethal mutations in several 
different types of viruses (Moreno et al. 1997, Cicin-Sain et al. 2005), including coronaviruses 
(Kim et al. 1997, Stalcup et al. 1998). By conferring mutational robustness, coinfection could 
enable the virus population to sample a broader sequence space, increasing the probability of 
producing a variant with the ability to infect a new host species.  
At the moment, the role of mutational robustness in host range expansion is purely 
speculative. Although robustness may increase the likelihood of producing a variant with an 
expanded host range, the success of this variant relies on how well it can adapt to the new host. 
Since robustness can either hinder or facilitate adaptation depending on various conditions, the 
role of robustness in host range expansion is complex (Draghi et al. 2010, Stern et al. 2014). 
Further experimental studies are needed both to confirm the mutational robustness of 
coronaviruses and to determine its contribution to host range expansion. 
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CONCLUSION 
The increasing prevalence of emerging pathogens heightens the need to understand the 
biochemical and evolutionary dynamics of host range expansion events. While coronaviruses 
have been circulating in the human population for over hundreds of years, the recent emergence 
of highly pathogenic strains and the lack of effective vaccines or therapeutics emphasizes the 
need to prioritize these studies. For SARS-CoV and MERS-CoV, the specific factors 
contributing to the host range expansion are still unclear. Elucidating the selective pressures 
imposed on the virus populations will help reveal the specific path of emergence for SARS-CoV 
and MERS-CoV. Additionally, the isolation of MERS-CoV and BtCoV-HKU4 reveals an 
increased variation in the receptors that coronaviruses can utilize, adding DPP4 to the list of 
already identified human receptors, APN (hCoV-229E) and ACE2 (SARS-CoV, hCoV-NL63). 
This discovery shows the enhanced variation and functionality of coronavirus spike proteins, but 
reduces the expected power of screening potential for emerging coronaviruses based on receptor 
utilization. 
Currently, we know that MERS-CoV permissivity is primarily mediated by the 
interactions between the host-cell receptor and the MERS-CoV RBD. Other areas of research 
that require additional investigation include the role of host cell proteases and innate immune 
antiviral defense pathways, which for the most part are understudied in coronavirus host range 
expansion research. For MERS-CoV, permissive and nonpermissive DPP4 orthologs have been 
identified and tested experimentally (de Wit et al. 2013a, de Wit et al. 2013b, Cockrell et al. 
2014, Coleman et al. 2014, Raj et al. 2014, Song et al. 2014, van Doremalen et al. 2014). 
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Together, this work has generated a useful toolkit for identifying the specific residues or 
biochemical characteristics that allow or prevent MERS-CoV infection. These studies can inform 
the development of small animal models, vaccines, and therapeutics, in addition to revealing the 
mutational path that allowed MERS-CoV to expand its host range into humans. 
Here, I present work that investigated the biochemical determinants of MERS-CoV host 
range. Upon emergence, it was found that the MERS-CoV host cell receptor was DPP4 and that 
while it could utilize hDPP4, cDPP4, and bDPP4, it was unable to utilize the DPP4 molecules 
from traditional small animal models, including mice, ferrets, hamsters, and guinea pigs. With 
this landscape, understanding the biochemical determinants of infection could not only help in 
the generation of a small animal model, but also allow us to better understand how MERS-CoV 
was able to expand its host range into humans.  
We found that two amino acids changes in mDPP4 could allow it to support MERS-CoV 
infection. These two mutations (A288L and T330R) stabilize an important hydrophobic core in 
the MERS-CoV RBD and remove a sterically hindering glycosylation site, respectively (Figures 
1.5 and 1.7). This data were used to generate a transgenic mouse model using the CRISPR/Cas9 
genome editing technique. Validation studies of the transgenic mouse model are currently 
underway. Additionally, these data were used to investigate whether there was a broader 
signature of permissivity among other nonpermissive DPP4 orthologs. Namely, fDPP4 and 
haDPP4 also share a nonconserved glycosylation site that could act to block MERS-CoV 
infection, whereas gpDPP4 has a downstream glycosylation site that is shared with bDPP4 
(Figure 2.2A). Removing these glycosylation sites, while important, is not sufficient on its own 
to confer permissivity (Figure 2.3A). Rather, additional complex determinants mediate MERS-
CoV permissivity in these DPP4 orthologs (Figure 2.7). 
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Although MERS-CoV mouse models have been developed, a more valuable resource 
would be a mouse-adapted MERS-CoV strain. However, due to the presence of a glycan as a 
barrier to infection by MERS-CoV, we hypothesize that extensive remodeling of the MERS-CoV 
RBD would need to take place before it could overcome the mDPP4 glycosylation site. 
Adaptation experiments using a host invasion strategy (Figures 3.1 and 3.2) did not result in a 
successful host range variant (Figures 3.6 and 3.7). Because of the population’s inability to 
produce enough genetic variation to sample potential host range variants, I developed a 
framework for producing a MERS-CoV mutator allele (Figure 4.1). By combining population 
biology theory and high-throughput sequencing techniques, a low-fitness cost mutator allele can 
be identified (Figure 4.3) to be used for host range expansion experiments. Namely, can a 
mutator allele promote host range expansion in the context of coronaviruses? Although a MERS-
CoV mutator appears to be more difficult to produce compared to SARS-CoV and MHV 
(Eckerle et al. 2007, Eckerle et al. 2010), the coronavirus system can still act as a useful system 
for studying the impact of mutation rate on host range expansion. Measuring the mutation rate of 
MERS-CoV and closely related viruses can reveal whether an increased production of genetic 
variation played a role in its emergence into humans. 
While ecological factors play an important role in host range expansion, several inherent 
biological properties may increase the emergence probability of a viral strain. In addition to 
mutator alleles, these evolutionary mechanisms can include recombination and mutational 
robustness. Recombination occurs at high frequencies in vitro (Baric et al. 1990), suggesting that 
it has the potential to shape the evolutionary trajectories of coronavirus populations. 
Recombination has been implicated in the SARS-CoV jump (Rest and Mindell 2003, Li et al. 
2006), but also see (Holmes 2003, Demogines et al. 2012). It has been suggested to play a role in 
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the evolution of MERS-CoV (Dudas and Rambaut 2016) and this hypothesis will become more 
resolved as the number of bat coronavirus sequence samples increases. Additionally, high 
mutational robustness has the potential to allow coronaviruses to tolerate the mutations that 
would allow them to expand their host range. Evaluating the mutational robustness for SARS-
CoV and MERS-CoV can help detail whether robustness plays a role in coronavirus evolution. 
While the genetics and biochemistry of coronaviruses have been well studied, we know 
very little about the underlying evolutionary mechanisms that result in cross-species transmission 
and emergence into humans. Coronaviruses can act as an important model system for addressing 
the fundamental principles of host range evolution. The SARS-CoV and MERS-CoV infectious 
clone systems (Yount et al. 2003, Scobey et al. 2013) allow robust reverse genetics experiments 
and the presence of a proofreading mechanism in coronaviruses allows for the production and 
study of mutator phenotypes. These mutator phenotypes also provide a unique tool for studying 
robustness, since strains with higher mutation rates are expected to evolve greater robustness 
than a wildtype strain (Wilke et al. 2001). Additionally, SARS-CoV and MERS-CoV have well 
characterized virus-host cell receptor interactions as well as known human monoclonal 
antibodies that target the RBDs of each virus. While experimental evolution has been scarce in 
the coronavirus world, the toolset is present for strong collaborations with evolutionary 
biologists to help better understand the evolutionary mechanisms that govern highly relevant 
pathogens. Ideally, understanding the host range expansion of emerging pathogens would enable 
us to screen circulating virus populations and identify strains that are most likely to emerge into 
the human population. Investigating the biochemical determinants and evolutionary mechanisms 
that govern coronavirus host range expansion can allow us to protect public health and better 
understand the processes which govern viral evolution.   
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APPENDIX A: PHYLOGENETIC TREE CORONAVIRUS STRAINS 
 
Species group Accession  number 
   
Avian IBV (AIBV) 3 NC_001451.1 
BCoV-SC2013 2c KJ473821.1 
Betacoronavirus HKU24 (BCoV-HKU24) 2a NC_026011.1 
Bovine CoV (BoCoV) 2a NC_003045.1 
BtCoV-133-2005 2c NC_008315.1 
BtCoV-273 2b DQ648856 
BtCoV-279-2005 2b DQ648857.1 
BtCoV-CDPHE15 1b NC_022103.1 
BtCoV-HKU10.H 1b JQ989273.1 
BtCoV-HKU10.R 1b NC_018871.1 
BtCoV-HKU2 1b NC_009988.1 
BtCoV-HKU3 2b DQ084199 
BtCoV-HKU4 2c NC_009019 
BtCoV-HKU5 2c NC_009020 
BtCoV-HKU8 1b NC_010438.1 
BtCoV-HKU9.1 2d NC_009021 
BtCoV-HKU9.5.1 2d HM211098.1 
BtCoV-SL-CoV-WIV1 2b KF367457.1 
Canine CoV A76 (CCoV-A76) 1a JN856008.2 
CoV-Neoromicia 2c KC869678.4 
Equine CoV (ECoV) 2a EF446615 
Feline CoV UU54 (FCoV-UU54) 1a JN183883.1 
Giraffe CoV (GiCoV) 2a EF424623 
HCoV-229E 1b KF514433.1 
HCoV-HKU1 2a DQ339101 
HCoV-NL63 1b KF530114.1 
HCoV-OC43 2a AY903459 
Human Enteric CoV (HECoV-4408) 2a FJ415324 
MERS-CoV 2c JX869059.2 
MHV-A59 2a AF029248 
PEDV 1b NC_003436.1 
PHEV 2a DQ011855 
PRCV 1a DQ811787.1 
Rabbit CoV HKU14 (RCoV-HKU14) 2a NC_017083.1 
Rat CoV (Rt-CoV) 2a NC_012936 
SARS-CoV 2b AY278491 
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TGEV Purdue 1a DQ811789.2 
Turkey CoV (TCoV) 3 EU022526.1 
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APPENDIX B: PHYLOGENETIC TREE DPP4 ORTHOLOGS 
 
Species Latin name Genbank Length 
    
African savanna elephant Loxodonta africana XM_010586282.1 2412 
Alpaca Vicugna pacos XM_006196217.2 3494 
Alpine marmot Marmota marmota marmota XM_015479253.1 3556 
American alligator Alligator mississippiensis XM_014599323.1 2781 
American pika Ochotona princeps XM_004577330.2 3300 
Angola colobus Colobus angolensis palliatus XM_001947095.1 4058 
Arabian camel Camelus dromedarius KF574263.1 2301 
Bactrian camel Camelus bactrianus XM_010971448.1 3376 
Bald eagle Haliaeetus leucocephalus XM_010569541.1 2982 
Barn owl Tyto alba XM_009969592.1 1958 
Bison Bison bison bison XM_010858966.1 3992 
Black flying fox Pteropus alecto XM_006921123.2 3914 
Blackstripe livebearer Poeciliopsis prolifica GBYX01453948 2860 
Bolivian squirrel monkey 
Saimiri boliviensis 
boliviensis 
XM_010329649.1 3275 
Brandts bat Myotis brandtii XM_0058593272.2 3467 
Cattle Bos taurus BC102523.1 2497 
Cheetah Acinonyx jubatus XM_015082793.1 2498 
Chicken Gallus gallus NM_001031255.2 3300 
Chimney swift Chaetura pelagica XM_009996287.1 2248 
Chimpanzee Pan troglodytes XM_016949951.1 4074 
Chinese alligator Alligator sinensis XM_014526682.1 2875 
Chinese hamster Cricetulus griseus XM_007610182.2 3517 
Chinese soft-shelled turtle Pelodiscus sinensis XM_006114841.2 3987 
Chinese tree shrew Tupaia chinensis XM_006160271.1 2875 
Common garter snake Thamnophis sirtalis XM_014060153.1 2857 
Common Pipistrelle Pipistrellus pipistrellus KC249974 2283 
Common starling Sturnus vulgaris XM_014880883.1 3414 
Coquerels sifaka Propithecus coquereli XM_012655850.1 3257 
Crab-eating macaque Macaca fascicularis XM_015432296.1 3245 
Damara mole rat Fukomys damarensis XM_010606844.1 2718 
Davids Myotis (vesper bat) Myotis davidii XM_006766490.2 3455 
Degu Octodon degus XM_004629976.1 2385 
Dog Canis lupus familiaris XM_014110860.1 3291 
Domestic cat Felis catus NM_001009838.1 2573 
Domestic ferret Mustela putorius furo KF574264.1 2298 
Domestic guinea pig Cavia porcellus XM_013142395.1 3431 
Egyptian jerboa Jaculus jaculus XM_004651712.1 3319 
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Egyptian rousette Rousettus aegyptiacus XM_016146442.1 3225 
European shrew Sorex araneus XM_004608172.1 2298 
Giant panda Ailuropoda melanoleuca XM_011231867.1 3558 
Goat Capra hircus KF574265.1 2298 
Golden eagle Aquila chrysaetos canadensis XM_011580051.1 3485 
Golden hamster Mesocricetus auratus NM_001310571.1 2295 
Golden snub-nosed 
monkey 
Rhinopithecus roxellana XM_010361854.1 3899 
Gray mouse lemur Microcebus murinus XM_012735717.1 3568 
Gray short-tailed opossum Monodelphis domestica XM_007494268.2 3764 
Green monkey Chlorocebus sabaeus XM_007965152.1 3803 
Horse Equus caballus XM_005601544.2 3432 
Humans Homo sapiens NM_001935.3 3913 
Jamaican fruit-eating bat Artibeus jamaicensis KF574262.1 2298 
Japanese quail Coturnix japonica XR_001556650.1 2252 
Killer whale Orcinus orca XM_012538174.1 3408 
Large flying fox Pteropus vampyrus XM_011358549.1 3954 
Little brown bat Myotis lucifugus XM_014445986.1 3553 
Little egret Egretta garzetta XM_009640707.1 2324 
Long-tailed chinchilla Chinchilla lanigera XM_005393319 3887 
Mallard Anas platyrhynchos XR_001194974.1 1952 
Mandrill Mandrillus leucophaeus XM_011991008.1 4060 
Mas night monkey Aotus nancymaae XM_012440525.1 3585 
Medium ground-finch Geospiza fortis XM_014306574.1 2274 
Minke whale 
Balaenoptera acutorostrata 
scammoni 
XM_007183309.1 3605 
Mouflon sheep Ovis aries musimon XM_012169318.2 3993 
Mouse Mus musculus NM_001159543.1 3654 
Naked mole rat Heterocephalus glaber XM_013076128.1 2288 
Natal long-fingered bat Miniopterus natalensis XM_016196976.1 3403 
Northern pike Esox lucius XM_010890872.1 2561 
Northern white-cheeked 
gibbon 
Nomascus leucogenys XM_003266171.2 4062 
Olive baboon Papio anubis XM_009182328.1 3641 
Ords kangaroo rat Dipodomys ordii XM_013029133.1 3555 
Pacific walrus Odobenus rosmarus XM_004410199.2 3412 
Peregrine falcon Falco peregrinus XM_013296766.1 2202 
Philippine tarsier Tarsius syrichta XM_008048884.1 3262 
Pig-tailed macaque Macaca nemestrina XM_011744180.1 3541 
Platypus Ornithorhynchus anatinus XM_001512829.2 3300 
Prairie deer mouse 
Peromyscus maniculatus 
bairdii 
XM_006984654.2 3734 
Prairie vole Microtus ochrogaster XM_013346055.1 3504 
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Pygmy chimpanzee Pan paniscus XM_008974411 3541 
Rhesus macaque Macaca mulatta NM_001039190.2 3596 
Rhinoceros hornbill Buceros rhinoceros silvestris XM_010133207.1 2276 
Rock pigeon Columba livia XM_013367520.1 2444 
Saker falcon Falco cherrug XM_014282916.1 2202 
Sheep Ovis aries KF574268.1 2298 
Small-eared galago Otolemur garnettii XM_012808448.1 2590 
Sooty mangabey Cercocebus atys XM_012038558.1 3553 
Sperm whale Physeter catadon XM_007105293.1 3407 
Star-nosed mole Condylura cristata XM_004674874.2 3490 
Sumatran orangutan Pongo abelii NM_001132869.1 3411 
Swan goose Anser cygnoides domesticus XM_013171141.1 2859 
Tasmanian devil Sarcophilus harrisii XM_003763903.2 2365 
Western lowland gorilla Gorilla gorilla gorilla XM_004032706.1 4068 
White-tailed eagle Haliaeetus albicilla XM_009918923.1 2441 
White-tufted-ear marmoset Callithris jacchus XM_002749392.2 3838 
Wild Bactrian camel Camelus ferus XM_006176809.2 3389 
Wild boar Sus scrofa NM_214257.1 2400 
Wild yak Bos mutus XM_005897282.2 3633 
Zebra finch Taeniopygia guttata XM_012574811.1 3336 
Zebrafish Danio rerio NM_00161337.1 2878 
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